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1. INTRODUCTION 
1.1 Immune complex glomerulonephritis 
 
The most common form of immune complex glomerulonephritis include, IgA 
nephropathy, post infectious glomerulonephritis and autoimmune e.g. lupus nephritis. 
Lupus nephritis is a form of immune-complex glomerulonephritis that remains a leading 
cause of morbidity and mortality in SLE. The concept that the pathogenesis of many 
common forms of idiopathic glomerulonephritis, such as membranous nephropathy and 
Immunoglobulin-A nephropathy, is related to immune complexes is widely accepted. 
Although anti-dsDNA was once thought to cause glomerulonephritis by forming 
complexes with DNA that are passively trapped in the glomeruli (1), many investigators 
now believe that anti-double stranded (ds)DNA antibodies are pathogenic to the kidney 
via direct (cross-reactivity) or indirect (via a nuclear-antigen bridge) binding to 
glomerular structures (2). SLE is characterized serologically by a variety of 
autoantibodies to deoxyribonucleic acid (DNA), ribonucleic acid (RNA), other nuclear 
antigens (e.g. Smith, Ro, La) and cytoplasmic antigens. The presence of anti-dsDNA 
antibodies has been linked most closely to pathogenicity (3), in particular the renal 
histological activity score (4). 
 
1.2 Pathophysiology of lupus nephritis  
Anti-double stranded (ds)DNA antibodies are thought to play a crucial role in the 
pathogenesis of lupus nephritis, a common form of immune complex glomerulonephritis 
(2, 5). Clinically, anti-dsDNA antibodies can be eluted from the kidneys of patients with 
active nephritis, suggesting that these antibodies might be important in the induction of 
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tissue damage (1, 6). In many patients with SLE, increased renal disease activity is 
associated with rising titers of anti-DNA antibodies, while prophylactic treatment of 
serologically active lupus patients with corticosteroids significantly reduces the number 
of subsequent disease flares (7). Accumulating data suggest that nucleosomes are the 
mediators of autoantibody-related glomerular immune-complex deposition, along with 
the major autoantigens that elicit the autoimmune response (8, 9, 10). Autoantibodies 
reactive to nucleosomes have been detected both in patients with lupus and in urine 
models, even prior to the development of anti-dsDNA and anti-histone antibodies (11). 
Upon renal deposition, the immune complex–mediated activation of complement through 
the classic pathway is traditionally believed to be a major mechanism by which tissue 
injury occurs (12). Further a role for self-DNA in the pathogenesis of SLE and associated 
lupus nephritis has been proposed. Recent studies on epigenetics, including DNA 
methylation and its regulatory enzymes, seem likely to contribute to elucidation of the 
pathogenesis of SLE and associated nephritis (13). It has been shown that methylation of 
CpG-motif prevents their stimulatory effect on B cells (14) and genomic DNA released 
by dying cells has been shown to induce the maturation of antigen-presenting cells (15). 
Interestingly, known inhibitors of DNA methylation can induce SLE in humans (16). 
Furthermore, in vertebrates inhibitory DNA sequence elements counterbalance the 
immunostimulatory effects of unmethylated CpG-DNA (17). Taken together these 
findings point towards the role of endogenous CpG DNA in the pathogenesis of SLE and 
associated lupus nephritis. However, the systemic pathophysiology and end organ 
damage during lupus nephritis that is initiated by the renal deposition of immune 
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complexes is driven by a complex interplay of events led by the innate and adaptive 
components of the immune system. 
 
1.2.1 Overview of the immune system 
The immune system is an integrated body system of organs, tissues, cells, and cell 
products such as antibodies that differentiates self from nonself and neutralizes 
potentially pathogenic organisms or substances. The immune system acts as a defence 
against foreign pathogens such as viruses, bacteria, and parasites. Immune system is often 
divided into the two different sections of innate and adaptive immunity (Table.1), the 
former encompassing unchanging mechanisms that are continuously in force to ward off 
noxious influences, and the latter responding to new influences by mounting an immune 
response.  
Table 1 
 
 
Property Innate immunity Adaptive immunity 
Triggering molecules repetitive molecular 
units 
antigen + association 
structures 
Recognition mechanism direct indirect 
Onset of response immediate (hours) delayed (days) 
Clonal expansion of responder cells No yes 
Induces inflammation  always often 
Memory (to prevent reinfection) No yes 
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 Figure. 1 
The innate immune responses involve: Phagocytic cells 
(neutrophils, monocytes, and macrophages); cells that release 
inflammatory mediators (basophils, mast cells, and 
eosinophils); natural killer cells (NK cells); and molecules 
such as complement proteins, acute phase proteins, and 
cytokines. Examples of innate immunity are anatomical barriers, mechanical removal, 
chemicals, the complement pathways, phagocytosis, inflammation, fever, and the acute 
phase response. The adaptive immunity usually involves: Antigen-presenting cells 
(APCs) such as macrophages and dendritic cells (DCs); the activation and proliferation of 
antigen-specific B-lymphocytes; the activation and proliferation of antigen-specific T-
lymphocytes; and the production of antibody molecules, cytotoxic T-lymphocytes 
(CTLs), activated macrophages and NK cells, and cytokines. There are two major 
branches of the adaptive immune responses: cell-mediated immunity and humoral 
immunity. Cell-mediated immunity involves the production of cytotoxic T-lymphocytes, 
activated macrophages, activated NK cells, and cytokines in response to an antigen and is 
mediated by T-lymphocytes. Humoral immunity involves the production of antibody 
molecules in response to an antigen and is mediated by B-lymphocytes. In this manner 
the innate and adaptive immune systems work in a concerted fashion to protect and 
organism from disease causing infectious agents. However, loss of tolerance mechanisms 
of the body against substances and tissues normally present in the body can lead to a 
condition termed as ‘autoimmune disease’. Amongst others, five clinical disorders that 
10 
  
are autoimmune in nature and most common in occurrence include: rheumatoid arthritis 
(RA), systemic lupus erythematosus (SLE), insulin-dependent diabetes mellitus (IDDM), 
autoimmune thyroid disease and multiple sclerosis (MS) (18, 19, 20, 21, 22). The 
development of such autoimmune diseases involves mainly three factors comprising; 
genetic predisposition, environmental factors and immune dysregulation (Figure. 1). 
Among the genetic markers of predisposition to autoimmune disease are specific sets of 
genes for MHC molecules that both shape and regulate the specificity of the adaptive 
immune response. The mammalian genetic makeup determines not only how the immune 
system deals with antigenic challenges from the environment, but also how the immune 
system is regulated to remain tolerant towards self (23). During SLE loss of such self 
tolerance mechanisms occurs and autoreactive T cells that are necessary to activate B 
cells, are further stimulated to proliferate and produce autoantibodies by the elevated 
levels of proinflammatory cytokines (24, 25) contributing to disease in lupus nephritis. 
Furthermore, the autoantibody production may be enhanced further by T and B cell 
interaction providing anti-apoptotic signals (26, 27, 28), which may additionally 
contribute to autoantibody production and their renal deposition leading to tissue damage. 
Additionally, IL-12 levels are downregulated by IL-10, with lower levels correlating with 
increased disease activity and nephritis (29, 30). Further a pathogenic role for cytokines 
such as IL-6, IL-10 and IL-12 has been identified, in SLE and associated lupus nephritis, 
through a number of studies (31, 32, 33). Understanding of these and additional 
mechanisms involved in the pathogenesis of lupus nephritis has provided a basis for 
developing effective therapies. 
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Current therapies 
Mycophenolate mofetil : (34, 35)  
Rituximab (CD20 antibody): B cell depleter (36, 37) 
 
Table 2 
Biological therapies in development for SLE
Therapy Mechanism of action Trials 
 Recombinant IL-1 
receptor antagonist 
(Anakinra) 
IL-1: potential role in 
development and 
maintenance of 
inflammation in SLE. IL-
1RA; physiological 
antagonist to IL-1 
Well tolerated. Principally 
effective (transient) for arthritic 
symptoms. Reduction in C3 and 
C4 (38, 39) 
Use in NZB/WF1 mice delayed 
disease onset and autoantibody 
production (40) 
Anti-IL-10 
monoclonal antibody 
IL-10; pleiotropic cytokine, 
induces B cell 
differentiation 
  In clinical trial improved joint and 
cutaneous symptoms and 
suppressed SLE (41) 
B cell tolerogens (LJP 
394) 
Synthetic molecule 
composed of multiple B 
cell dsDNA epitopes 
attached to non 
immunogenic carrier. Bind 
to anti-dsDNA receptors; 
modulates B cell responses, 
anergy and thus cessation 
of autoantibody production 
Randomized, DBPC trial 
Serological improvement but 
minimal reduction in renal flares 
(42) 
Anti-B lymphocyte 
stimulator 
anti-BLys modulates B cell 
immune responses by 
(BLyS) reduction of 
apoptosis, interference in B 
cell development and 
differentiation 
Phase I study:  
reduction in immunoglobulin and 
anti-dsDNA titres (43) 
 
Phase II trial under way 
DBPC: double-blind placebo-controlled; IL-1: interleukin 1; IL-1RA: interleukin I 
receptor antagonist; C3: complement 3; C4: complement 4; IL-10: interleukin 10 
 
Adapted and modified (44). 
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1.2.2 Therapeutic approaches in treatment of lupus nephritis 
In the past 40 years, prognosis for patients with lupus nephritis has improved, with 10-
year survival now approximately 90% (45, 46). This is probably because a combination 
of earlier disease diagnosis and due in part to the availability of multiple serological tests 
for SLE, use of steroids, other immunosuppressive agents, availability of renal dialysis 
and transplantation. More recently, advancements in the understanding of molecular 
mechanisms involved in pathogenesis of SLE have translated to the development of novel 
therapies (Table 2), offering possible alternatives for this patient cohort (44). However, 
the potential for significant morbidity and mortality remains in the group of patients with 
partially responsive or treatment resistant disease. Thus, prompting additional research 
efforts for discovery of more reliable means of treating the underlying disease. One of the 
major concerns in this regard is the poorly known molecular mechanisms involved in the 
pathogenesis of SLE and associated lupus nephritis. Elucidating the path mechanisms 
leading to lupus and the commonly associated nephritis not only would broaden our 
understanding for the cause but would also enable to discover more promising preventive 
or curative therapeutic remedies. 
 
1.2.3 Infections and their common association to lupus nephritis 
A common association of microbial infections may be linked not only to induction but 
also progression of pre-existing autoimmune disease such as lupus (47). The infectious 
stimuli, such as viral or bacterial agents that infect individuals affected by SLE, are 
commonly known inducers of disease flares and may lead to organ damage and/or 
dysfunction as seen in immune-complex glomerulonephritis. This puts the patient at a 
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further risk of disease aggravation worsened due to overt immune activation during 
intercurrent infections. It is known that viral components can trigger disease activity in 
SLE or autoimmunity in general (48), but the involved mechanisms remain poorly 
defined. It is believed that during viral infections, pathogen recognition and subsequent 
induction of adaptive immune responses might interfere with the control of self-tolerance 
in susceptible individuals. Likewise, experimental studies with rodents suggest that 
injection of synthetic CpG-ODN (a bacterial DNA analogue) can exacerbate underlying 
autoimmune tissue injury e.g. glomerulonephritis, experimental encephalomyelitis, 
collagen-induced arthritis or SLE (49, 50, 51, 52). Further during infection, recognition 
and mounting of an appropriate immune response for combating the pathogen, is initiated 
by Toll-like receptors (TLRs), a family of receptors that sense conserved pathogen 
associated molecular patterns (PAMPs). Besides recognition of foreign antigens to 
initiate immune responses against the invading pathogens, TLRs are known to sense 
certain endogenous molecules (Table 3). By virtue of the latter property TLRs and their 
ability to modulate innate and adaptive immunity may be expected to affect disease 
activity in autoimmune SLE-associated lupus nephritis and other forms immune complex 
glomerulonephritis. 
 
1.3 Toll-like receptors as immune sensors of microbial infections  
Infectious microbes are recognized by our immune system so as to exert antimicrobial 
responses. A family of receptors that commit themselves to this cause are the TLRs (53). 
TLRs were originally identified in Drosophila, where they were found to play a major 
role in protection from fungal infections (54). 
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Table 3 
   Potential endogenous ligands  
Toll-like 
receptor 
Exogenous ligands* Ligand 
 
TLR1 & 2 Tri-acyl lipopeptides (bacteria)    
TLR2 Peptidoglycan (Gram-positive bacteria) Heat shock proteins 
  Lipoteichoic acid (Gram+ bacteria) High mobility group box protein 1 
  Lipoarabinomannan (mycobacteria)   
  Glycophospholipids (Trypanosomes)    
  Glycolipids (Treponema), Porins 
(Neisseria), Zymogen (fungi), 
Lipopeptides 
 
TLR3 Double-stranded RNA (virus), SiRNA 
(55) 
mRNA 
TLR4 Lipopolysaccharides, lipid A (Gram-
negative bacteria) 
Heat shock proteins 
  Taxol (plant) High mobility group box protein 1 
  Protein F (respiratory syncytial virus) Fibronectin extra domain A 
  Hyphae (Aspergillus) Fibrinogen  
  HSP60 (Chlamydia) Lung surfactant protein A  
  Viral envelope proteins Low density lipoprotein  
    Heparan sulphate  
    Hyaluronan fragments  
TLR5 Flagellin (bacteria)  
TLR6 & 2 Di-acyl lipopeptides  
TLR7 Single-stranded RNA (viral)  
TLR8 Single-stranded RNA (viral)  
TLR9 DNA (bacteria & Herpes simplex 
virus), hemozoin (56) 
DNA  
TLR11 Uropathogenic Escherichia coli, 
profillin-like protien (57) 
 
 
Adapted and modified (53) 
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There are at least 11 currently identified mammalian orthologues, and these TLRs bind a 
remarkably diverse array of bacterial, viral, fungal and interestingly self molecular 
patterns (Table 3) (58). The basic structural features of the TLR family include an 
extracellular domain made up of multiple leucine-rich repeats and a highly conserved 
cytoplasmic signaling domain. The extracellular-domain forms a horseshoe-shaped 
solenoid with a broad hydrophobic surface that may account for the promiscuous ligand 
reactivities documented for TLR2 and TLR4 (58, 59). The cytoplasmic domain is shared 
with interleukin-1 receptor (IL-1R) family members and is commonly referred to as the 
Toll/IL-1R (TIR) domain. It follows that Toll and IL-1 family members use common 
adapter molecules, including myeloid differentiation factor 88 (MyD88), as part of their 
signaling cascades. Heterogeneous expression patterns of the nucleic acid specific TLRs 
on leukocyte subpopulations and the discovery of TLR-specific signaling pathways 
support specific types of immune responses for specific ligand-TLR interactions (60, 61). 
TLRs are differentially expressed by a range of cell types including macrophages, 
monocytes, dendritic cell subsets, B cells, a variety of endothelial and epithelial cell types 
(60). Monocytes, macrophages, and DCs routinely respond to TLR engagement by the 
production of proinflammatory cytokines and upregulation of costimulatory molecules 
(58). The B-cell response to TLR ligands is further characterized by proliferation and 
antibody production, and the natural IgM produced by these cells may facilitate the 
clearance of microbial particles as well as apoptotic or necrotic cell debris. This rapid 
response on the part of the innate immune system serves two important roles: first, to 
initially contain infectious microbes and secondly, to activate the adaptive immune 
response. An over-exuberant innate immune response can, however, lead to toxic shock 
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or other sepsis-associated complications. Among the innate immune cells, immature DCs, 
which are capable of capturing pathogens by phagocytosis, express several kinds of 
TLRs. The immature DCs mature after the recognition of microbial components via 
TLRs. The mature DCs in turn present pathogen-derived antigen, express co-stimulatory 
molecules, secrete several inflammatory cytokines including IL-12, and interact with 
naive T cells. The naive T cells harboring the antigen-specific T cell receptor are 
instructed to develop into Th1 cells, and clonally expand to exhibit effective adaptive 
immune responses. Likewise, IL-6 produced as a result of DC activation through TLR 
ligation is involved in regulatory T-cell suppression and leads to increased autoreactivity 
(62). These and additional findings provide an ample evidence for involvement of TLRs 
in linking innate immunity to adaptive immunity not only in infection associated 
immunity but also autoimmunity. 
 
1.3.1 Toll-like receptors that sense nucleic acids 
A diverse of bacterial, viral or fungal molecular patterns is sensed by the TLRs that signal 
to mount an appropriate immune response. In this context, a subfamily of TLRs namely, 
TLR3, TL7, TLR8, and TLR9 form an interesting group of receptors specifically 
recognize nucleic acid motifs.  
TLR3: TLR3 is a detector of double-stranded (ds) RNA that may originate from single-
stranded (ss)RNA or dsRNA viruses (63, 64). Among the monocytic immune cell subsets 
TLR3 is expressed on murine macrophages; whereas, in humans TLR3 is exclusively 
expressed on myeloid DCs (63, 65, 66). It is believed that TLR3 recognizes secondary 
RNA structures as synthetic RNAs, mRNA, and small inhibitory RNA (siRNA) similarly 
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induce the production of type I interferons and proinflammatory cytokines. Viral dsRNA 
induces DC maturation through TLR3 (63). In addition, TLR3 has been reported to be 
expressed on various cells, such as astrocytes (67), uterine epithelial cells (68), and 
fibroblasts (69). These cells express TLR3 constitutively at low levels and upregulate 
TLR3 upon exposure to dsRNA or other TLR ligands. Most cell types express TLR3 in 
an endosomal compartment, which supports the idea that viruses need to be processed 
before their RNA can be exposed to TLR3. However, fibroblasts have been reported to 
express TLR3 also on their outer surface membrane (69). Apparently, viral RNA can act 
as a natural adjuvant that promotes loss of tolerance against presented endogenous or 
exogenous antigens and modulates the Th1/Th2 balance of the subsequent T cell response 
(70).  
TLR7 and TLR8: Similar to TLR3 and 9, TLR7 and 8 are expressed intracellularly in 
endosomes and recognize phagocytosed ligands on macrophages, DCs and B cells (71, 
72). TLR7 and TLR8 both recognize viral ssRNA as well as distinct synthetic guanosine 
analogues (58, 73). Certain U-rich or U/G-rich oligonucleotides presented as a complex 
with cationic lipids (but not in free form), induce recognition and activation by means of 
mouse TLR7 and human TLR8 (74). Activation of TLR7 and 8 on dendritic cells lead to 
their maturation and production of proinflammatory cytokines so as to exert a typical 
antiviral response (73).  
TLR9: Unmethylated cytosine-guanosine (CpG)-DNA, an important ligand for TLR9 
(75) has been widely employed for several immunotherapeutic purposes (76). The CpG 
dinucleotide is the stimulatory motif of bacterial and viral DNA (14). CpG-DNA is a B 
cell mitogen and a strong activator of plasmacytoid DCs in humans (72). CpG-DNA 
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complexed with other proteins induces an enhanced antigen-specific humoral and cellular 
immune response of the Th1 type (77). TLR9 resides in the endoplasmic reticulum but 
redistributes to late endosomes for the interaction with ingested CpG-DNA (71). Various 
synthetically manufactured CpG-oligodeoxynucleotides (ODNs) represent powerful tools 
for research in this field. A recent study described plasmodia hemozoin as another natural 
ligand for TLR9, which raises doubt against the concept that TLR9 recognizes specific 
nucleic acid sequences (56, 78). TLR9 might recognize particle-related secondary 
structures rather than specific DNA sequences. This is supported by the observation that 
the formation of DNA nanoparticles can modulate TLR9 signalling towards production 
of high levels of type I interferons (79). In particular IFN-α exposure or prolonged 
expression of IFN-α in vivo induces early lethal lupus and associated nephritis in 
susceptible mice (80). 
 
1.3.2 Nucleic acid-specific TLRs modulate autoimmunity 
Although under normal circumstances TLRs do not recognize self-molecules, signaling 
through these receptors may play important role in the loss of self-tolerance and 
induction of autoimmunity. Several recent studies reflect a major role for nucleic acid 
specific TLRs, in linking innate immunity (81, 82) to adaptive immunity (83). Recently 
TLR 3 and 7 engagement has been shown to convert T-cell autoreactivity into overt 
autoimmune disease, through release of IFNα-mediated upregulation of MHC I on 
pancreatic tissue (84). In another study replicase-based nucleic acid vaccines that 
generate dsRNA, which is recognized by TLR3 have been found to break self-tolerance 
and convert autoreactivity into overt disease (85). Leadbetter et al. observed that, in a 
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mouse model of systemic autoimmune diseases, the simultaneous activation of cell-
surface antigen receptors and TLR9 causes a particular subclass of self-immunoglobulin 
(IgG)2a, to be recognized by B cells as a pathogen and triggers T-cell-independent 
proliferation of B cells (77). In this study the role of mammalian DNA in activating 
TLR9 was confirmed using DNase treatment that rendered the immune complexes 
inactive.  In another study, DNA with unmethylated CpG motifs efficiently stimulated 
anti-DNA idiotype-expressing B cells (86). Another study identified plasmacytoid DCs to 
be activated by immune complexes containing nucleic acid released by necrotic or late 
apoptotic cells and lupus IgG leading to induction of interferon (IFN)-α production (87). 
IFNα has been recently identified as a crucial player in induction of autoimmunity by 
virtue of diverse array of effects it has on innate and adaptive immunity, and the potential 
mechanisms involved have been discussed in a detailed review by Theofilopoulos AN et 
al (88) A crucial role of DCs has been identified in autoimmune disease induction where, 
DCs loaded with a heart-specific self peptide were shown to induce CD4+ T-cell-
mediated myocarditis in nontransgenic mice. In this study, TLR3 or TLR2, 4 or 9 
stimulation in concert with CD40 triggering of self peptide-loaded DCs, was shown to be 
required for disease induction (89). Activation of APCs by TLR9 or TLR4 engagement 
can break self-tolerance and trigger the development of autoimmunity even in a 
genetically resistant strain such as B10.S mice, transgenic for a T cell receptor specific 
for the encephalitogenic protein peptide, that normally are resistant to spontaneous 
experimental allergic encephalomyelitis (EAE) (90).  
The ability of nucleic acid specific TLRs for pathogen control is widely accepted, 
but their role in autoimmunity is less well defined (91, 92). While, TLR9 is known to be 
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expressed on antigen presenting cells (APCs) and B cells, TLR3 is reported to be 
expressed on APCs and on various non-immune cells (67, 68, 69). Local tissue 
inflammatory responses through TLR activation, upon exposure to their ligands due to 
infection or by endogenous molecules can therefore be expected to contribute to end 
organ damage, such as lupus nephritis. Experimental studies with rodents suggest that 
exposure to synthetic CpG-ODN can exacerbate underlying autoimmune tissue injury e.g. 
experimental encephalomyelitis, collagen-induced arthritis or SLE (50, 51). TLR9 
activation by CpG–ODN has been shown to aggravate disease activity in spontaneous 
immune complex glomerulonephritis of MRLlpr/lpr mice (49, 52). Furthermore, TLR3 
activation is followed by a robust induction of IFN-responsive genes (61, 93, 94), of 
which IFN-α is a well-known pathogenic factor for SLE and associated nephritis (88, 
95). In SLE the interaction of CpG-DNA with TLR9 is of particular interest for the 
reasons that: 1. CpG-DNA is a B cell mitogen that allows T cell independent B cell 
proliferation and autoantibody production (77). 2. Immune complexes isolated from lupus 
patients activate TLR9 on DCs to produce IFN-α (96). 3. CpG DNA can aggravate 
autoimmune tissue injury locally by activation of tissue macrophages (50). Methylation 
of CpG-motif prevents their stimulatory effect on B cells (14). Additionally, genomic 
DNA released by dying cells can induce the maturation of APCs (15) while known 
inhibitors of DNA methylation can induce SLE in humans (16). Furthermore, in 
vertebrates inhibitory DNA sequence elements counterbalance the immunostimulatory 
effects of unmethylated CpG-DNA (17). It is known that certain synthetic ODNs with 
such inhibitory motifs have shown to block CpG-DNA-induced effects (97, 98, 99). 
However, experimental evidence for a pathogenic role of CpG motifs in self-DNA for 
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lupus is lacking. These and many other studies reveal a potential role for nucleic acid 
specific TLRs in modulating autoimmune disease and thus play a pathogenic role. 
However the contribution of nucleic acid specific TLRs in leading to infectious tissue 
injury leading to end organ damage such as that seen with immune complex 
glomerulonephritis is not clear. Moreover, considering their expression on intrinsic tissue 
cell types apart from the immune cell repertoire my have important implications in 
progression rather than induction of autoimmune tissue injury. 
 
1.4 Aim of the study 
In order to test the ability nucleic acid specific TLRs, namely TLR3 and 9 to modulate 
autoimmunity in MRLlpr/lpr mice it was hypothesized that: 1. Intercurrent infection 
induced exposure to viral dsRNA and can aggravate immune complex glomerulonephrits 
through TLR3 on specific cell types and 2. Bacterial as well as endogenous CpG DNA 
could drive lupus and synthetic inhibitory ODN would represent an appropriate tool to 
block the CpGDNA/TLR9 pathway in vivo. 
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2. MATERIAL AND METHODS 
2.1 Oligoribonucleotides & oligodeoxyribonucleotides (ODN)  
The following synthetic nucleotides were used for in vitro or in vivo studies: 
Polyinosinic-cytidylic acid (pI:C RNA) and Polydeoxyinosinic-deoxycytidylic acid (pI:C 
DNA) (dI:dC; Sigma-Aldrich, Steinheim, Germany), a synthetically made nucleotide 
sequence 3′-rhodamine-labeled dsRNA from human rhinovirus strain-16.11 with 
sequence (5′-AUCUGGGUUGUUCCCACCCAGAUCACCUACAUGG-rhodamine -3′ 
and (3′-UAGACCCAACAAGGGUGGGUCUAGUGGAUGUACC- 5′) (IBA, Göttingen, 
Germany) on a phosphorothioate backbone. The ODNs used were: ODN 2114: 5′-TCC 
TGG AGG GGA AGT -3′; CpG-ODN 1668: 5′-TCC ATG ACG TTC CTG ATG CT-3′, 
GpC-ODN 1720, 5′-TCC ATG AGC TTC CTG ATG CT-3′ (TIB Molbiol, Berlin, 
Germany) and 3'-rhodamine-labeled ODN 2114 on a phosphorothioate backbone.  
 
2.2 Animal studies 
In all animal studies, the mice were housed in filter top cages under a 12-hour light and 
dark cycle. Autoclaved water and standard chow (Sniff, Soest, Germany) were available 
ad libitum. All experimental procedures were performed according to the German animal 
care and ethics legislation and had been approved by the local government authorities. 
 
Effect of pI:C RNA exposure on disease activity in lupus 
For studying the effect of pI:C RNA exposure on disease activity during lupus, female 
MRLlpr/lpr mice were obtained from Jackson Laboratory (Bar Harbor, ME). 16-wk-old 
female MRLlpr/lpr mice were distributed into three groups, each consisting of 12 female 
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mice. From weeks 16 to 18, mice of all groups received intraperitoneal injections every 
other day as follows: 1) 50 μg of polyinosinic-cytidylic acid (pI:C) RNA (pI:C, Sigma-
Aldrich, Steinheim, Germany) in 100 μl of normal saline, 2) 50 μg of pI:C DNA (dI:dC; 
Sigma-Aldrich, Steinheim, Germany) in 100 µl of normal saline, and 3) 100 µl of normal 
saline. All mice were killed by cervical dislocation at the end of week 18 of age. For 
assessing renal TLR3 mRNA expression, kidneys were obtained from 5- and 20-wk-old 
female MRLlpr/lpr mice after sacrificing by cervical dislocation. The renal distribution 
of 3′-rhodamine-labeled dsRNA was assessed by injecting it intravenously into 
MRLlpr/lpr mice at the age of 16 wk. Renal tissue was collected 2 h later and subjected 
to further analysis as described below. For the identification of 3′-rhodamine-labeled 
viral dsRNA positive renal cells, co-staining was performed on crysections using rat anti-
F4/80 (Serotec, Oxford, UK; 1:50). 
 
Effect of ODN 2114 treatment on disease activity during lupus 
To determine the effect of ODN 2114 treatment on the disease activity during lupus, ten 
week old female MRLlpr/lpr mice were obtained from Harlan Winkelmann, Borchen, 
Germany. The mice were divided in 2 groups (n=10) and treated with either saline or 
ODN 2114 on alternate days from week 11 to 24 of age. Blood and urine samples were 
collected from each animal under ether anaesthesia at the end of the study and urine 
protein/creatinine ratio and serum blood urea nitrogen concentrations were determined 
using standard biochemical procedures. Serum dsDNA autoantibody IgG isotype titres 
were determined using a modified protocol for the respective Elisa kits (Bethyl 
Laboratories, Inc, Texas, USA). The procedure was modified in order to coat the sample 
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wells in the Elisa plate with murine dsDNA, in order to detect dsDNA specific IgG 
isotypes, while the remaining steps were carried out using the standard protocol described 
below. The mice were then sacrificed by cervical dislocation and the kidney, lung, liver 
and lymph nodes tissue pieces were collected, and processed for RNA isolation, 
immunostaining or paraffin fixed for histological analysis as described below. To assess 
the distribution of injected ODN 2114, 100 µg 3'-rhodamine-labeled ODN 2114 were 
injected intravenously into MRLlpr/lpr mice at the age 16 weeks. Tissues were collected 
2 hours later and processed for immunohistochemical staining on paraffin or cryosections 
as described elsewhere (Anders 2003). Co-staining was performed on cryosections using 
rat anti-F4/80 (Serotec, Oxford, UK; 1:50) and anti-IgG (Dianova; 1:100). 
 
Effect of ODN 2114 treatment on CpG ODN induced toxicity 
8 week old female 129Sv mice obtained from Taconic (Ry, Denmark) were used to study 
the effect of ODN 2114 on CpG ODN induced toxicity. In this experiment, the mice were 
divided into 5 different groups containing 5 animals, each of which received for 12 days, 
daily intraperitoneal injections of: 1) 100 µl normal saline (NS) as vehicle control, 2) 
CpG ODN (40µg in 100µl NS), 3) CpG ODN + ODN 2114 (40 µg in 100 µl NS), 4) 
ODN 2114 (40 µg in 100µl NS) and 5) GpC ODN (40 µg in 100µl NS). After completion 
of the treatment period the mice were sacrificed by cervical dislocation and the kidney, 
lung, liver and lymph nodes tissue pieces were collected, fixed with 10 % formalin and 
processed for periodic acid Schiff staining for the examining histomorphological 
changes. 
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In vivo B cell activation 
To test the ability of pI:C RNA to induce in vivo B cell activation, 4-wk-old MRLlpr/lpr 
mice bred in our own animal facility, were divided in three groups of two mice each. 
Each mouse received 500 μg/ml pI:C RNA, CpG, or pI:C DNA intraperitoneally, and the 
mice were killed after 24 h and spleens were collected and processed for flow cytometry 
as described below. To test the ability of ODN 2114 to suppress CpG-induced in vivo B 
cell activation, 4-wk-old MRLlpr/lpr mice, were divided in 5 groups of two mice each. 
All mice in different groups received intraperitoneal injections of 500 µg in 100µl saline 
CpG ODN, DN 2114 or CpG ODN together with ODN 2114, GpC ODN or saline alone 
respectively, and the mice were killed after 24 h and spleens were collected. Total spleen 
suspension from each mouse in all experimental groups was processed for flow 
cytometry as described below. 
 
Primary cell culture 
For both, pI:C and ODN 2114 treatment study or spleen monocytes and bone marrow 
derived dendritic cells (BMDCs) female MRLlpr/lpr mice 8-12 week of age were used. 
The mice were sacrificed by cervical dislocation and spleen and bone marrow were 
isolated for obtaining cultures of spleen monocytes or BMDCs, respectively. The whole 
spleen tissue was removed and processed for splenocytes isolation and culture as 
described below. For obtaining the BMDCs, whole bones from the femur from the fore- 
and hind-limbs were separated and processed as described in detail below.  
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2.3 Morphological and histological analysis 
From each mouse tissue collected as mentioned above, 2 µM thick paraffin-embedded 
sections were cut and processed for immunohistochemical staining performed on 
paraffin-embedded sections. Upon isolation the tissue pieces were placed in plastic 
histocassettes and dipped in formalin. The formalin solution was prepared using 500ml of 
40% Formaldehyde in PBS (32.5 g Na2HPO4 and 20 g NaH2PO4 in 4.5 L ddH2O water, 
pH 7.4). The blocks were then infiltrated and embedded with paraffin and sections were 
cut in ribbons and mounted on slides. Deparaffinisation followed by dehydration was 
carried out by incubating the sections in xylene, 100% absolute ethanol, 95%, 80% and 
50% ethanol followed by rinsing with PBS (2 changes, 3 minutes each). The sections 
were then treated with following primary antibodies were used: anti-TLR3 (1:50; 
IMG516; Imgenex, San Diego, CA), anti-TLR9 (kindly provided by Dr. Stefan Bauer, 
Technical University Munich, Germany, 1:50), anti–ER-HR3 (1:50; 
monocytes/macrophages; DPC Biermann, Bad Nauheim, Germany) (19), anti-CD3 
(1:100; BD Pharmingen, Hamburg, Germany), anti–smooth muscle actin (1:100; 
myofibroblasts, clone 1A4; Dako, Carpinteria, CA), anti-Ki-67 (DAKO, Hamburg, 
Germany, 1:25), anti-collagen I (LF-67, 1:50; provided by Dr. L.W. Fischer, National 
Institute of Dental Research, National Institutes of Health, Bethesda, MD), anti-CCL5 
(1:50; Peprotech, Rocky Hill, NJ), anti-CCL2 (1:50; Santa Cruz Biotechnology, Santa 
Cruz, A), and anti-IgG and anti-IgG2a (Dianova; 1:100). Negative controls included 
incubation with a respective isotype antibody. In the next step, a suitably labelled 
secondary antibody was used with respective detection system. For quantitative analysis 
for evaluation of glomerulonephritis glomerular cells were counted using microscope in 
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10 cortical glomeruli per section. The severity of the renal lesions was graded using the 
indices for activity and chronicity of lupus nephritis (100). Activity index included semi-
quantitative score of 4 active inflammatory lesions: 1. Glomerular leukocyte infiltration, 
2. Interstitial inflammation, 3. Glomerular karyorrhexis and 4. Cellular crescents; while 
chronicity index included semi-quantitative score of 3 inflammatory lesions: 1. 
Glomerular sclerosis, 2. Interstital fibrosis and 3. Tubular atrophy. Semiquantitative 
scoring of glomerular IgG deposits from 0 to 3 was performed on 15 cortical glomerular 
sections using a semiquantitative index as follows: 0 = no signal, 1 = low signal, 2 = 
moderate signal, and 3 = strong signal intensity. Peribronchial and pulmonary 
inflammation was arbitrarily graded from 0 (no inflammation) to 3 (severe 
inflammation). 
 
2.4 Cell culture and stimulation experiments 
Cell lines 
A murine mesangial cell line was maintained under standard culture conditions (in an 
incubator set at 37 °C supplied with 0.5% CO2) in Dulbecco’s modified Eagle’s medium 
(DMEM, Biochrom KG, Berlin, Germany) supplemented with 5% fetal calf serum (FCS) 
(Serum Supreme, BioWhittaker, Walkersville, MD, USA), penicillin100 U/ml and 
streptomycin 100 µg/ml as described (Complete DMEM medium). J774 mouse 
macrophages (American Type Culture Collection, Rockville, MD, USA) were grown in 
RPMI 1640 medium containing 10% heat-inactivated bovine serum, penicillin100 U/ml 
and streptomycin 100 µg/ml (complete RPMI medium).  
 
28 
  
Primary cultures  
Spleen monocytes: Spleen monocytes were obtained from spleens of 8-12 week old 
female MRLlpr/lpr mice. Whole spleens were isolated from the mice, placed in a petri-
dish containing complete RPMI medium and mashed with the help of forceps, this coarse 
suspension was then passed through a 30 micron steel wire mesh and collected in a sterile 
petri-dish. This suspension was then centrifuged at 1600 RCF for 4 min at 4 °C to obtain 
a pellet. The pellet thus obtained was washed with sterile PBS and the obtained pellet was 
resuspended in 0.83 % ammonium chloride solution so as to haemolyse the red cells. This 
was followed by a washing steps (2x) as mentioned above, passed through a pre-
separation filter to obtain single cell suspension (Miltenyi Biotec, Germany). Finally the 
cells were centrifuged, supernatant was discarded and the pellet was resuspended in an 
arbitrary volume of complete RPMI medium and cell counts were done. A desired 
number of cells was plated in 6 or 12 well plates and incubated at 37 °C for 24 hrs under 
standard culture conditions. The culture medium was replaced with fresh complete RPMI 
medium so as to obtain the adherent spleen monocytes, ready to be used for stimulation 
experiments. 
 
Bone marrow derived dendritic cells: Bone marrow from 8-12 week old female 
MRLlpr/lpr mice was isolated, processed and cultured using published methods (101).  
Bone marrow was isolated from the tibia and femurs from the fore and the hind limbs of 
the mice. The bones were cleaned thoroughly so as to remove any muscle tissue and the 
bone caps were carefully removed so as to expose the pink portion, which was cut at one 
of the ends of the bone. A 25-gauge needle fitted to a 1 ml syringe, filled with complete 
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RPMI medium, was inserted to one end of the bone so as to flush the bone marrow from 
the other end and collected in a sterile petri-dish. In this manner, all bones were carefully 
flushed to obtain bone marrow, which was then centrifuged at 1600 RCF for 4 min at 4 
°C to obtain a pellet. The pellet thus obtained was washed with sterile PBS and processed 
for hemolysis and washes as described above. Finally the cells were centrifuged, 
resuspended in an arbitrary volume of complete RPMI medium with 100 ng/ml human 
recombinant Flt3 ligand (Immunotools, Friesoyth, Germany) and cell counts were done. 
To select for bone marrow derived dendritic cells (BMDCs) for stimulation experiments, 
bone marrow isolates were cultured for 8 days in complete RPMI with 100 ng/ml human 
recombinant Flt3 ligand.  
 
B-cells: B cells were isolated from spleens of female MRLlpr/lpr mice using B Cell 
Isolation Kit (Miltenyi, Bergisch Gladbach, Germany) following the manufacturer’s 
protocol. Total spleens were harvested as described above and magnetic labelling was 
performed in which the cell pellet obtained from total spleen lymphocytes were 
resuspended in 40µl MACS buffer (PBS pH 7.2, supplemented with 0.5 % bovine serum 
albumin and 2 mM EDTA) per million total cells. 10µl biotin-antibody cocktail (biotin-
conjugated monoclonal antibodies against CD43 (Ly-48) (rat IgG2a), CD4 (L3T4) (rat 
IgG2b) and Ter-119 (rat IgG2b)) per million total cells, mixed well and incubated for 10 
min at 4-8 °C. 30µl buffer and 20µl anti-biotin microbeads were added to the cell and 
biotin-antibody cocktail, mixed and incubated for additional 15 min at 4-8 °C. The cells 
were then washed by adding 10-20x labelling volume and centrifuged at 300 xg for 10 
minutes and the supernatant was discarded. The cells were then resuspended in 500µl of 
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MACS buffer per 10 million total cells. This suspension was then applied on LS columns 
(Miltenyi, Bergisch Gladbach, Germany), that were pre-rinsed with 3 ml MACS buffer 
and the effluent was collected. The column was then washed 4 times using 3 ml MACS 
buffer and the remaining effluent was collected. Purity as determined by FACS analysis 
using CD45/B220-PE or Rat IgG2a as an isotype (BD Biosciences, Hamburg, Germany) 
revealed 97 % B cells after each isolation. 
 
Stimulation experiments 
For pI:C RNA treatment study; Spleen monocytes, BMDCs or mesangial cells were 
treated with medium control or different (indicated in figures) concentrations of pI:C 
RNA and pI:C DNA as a control. TLR9 ligand CpG-ODN 1668 was used as a control in 
selected cases. For ODN 2114 treatment study; J774 mouse macrophages were treated 
with with 1 μM CpG-ODN 1668, 1μg/ml LPS, with or without various concentrations of 
ODN 2114, while medium served as control. Similar concentrations were used in the B 
cell proliferation assay. In all stimulation experiments all cell types were unstarved 
(unless mentioned otherwise) and were incubated for a period of 24 hours under standard 
culture conditions and culture supernatants were collected for cytokine measurements and 
cells were harvested either for RNA isolation as described below or for flow-cytometric 
analysis.  
 
2.5 Cytokine Elisa, nitrite and B cell proliferation assay: 
Elisa: Cytokine levels in sera or cell culture supernatants were determined using 
commercial Elisa kits: IL-6, IL-12p70, CCL2 (all OptEiA, BD Pharmingen), IFN-α 
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(R&D Systems Inc, USA), and CCL5 (Duoset, R&D Systems Inc, USA) following the 
protocol provided by the respective manufacturers. The 96-well plate was first coated 
with 100µl/ well capture antibody (anti-mouse cytokine) at recommended dilution in 0.2 
M Sodium phosphate buffer of specified pH and placed overnight at 4 °C. The wells were 
then aspirated, washed with >200 µl wash buffer (PBS pH 7 with 0.05 % Tween-20) and 
the plate was blocked with >200 µl/well assay diluent (PBS pH 7 with 10 % FCS) and 
incubated at room temperature for 1 hour. This was followed by aspiration, 2 washes as 
described above, and 100 µl of standard or sample was pipetted to appropriate well and 
the plate was incubated for 2 hours at room temperature. The plate was then aspirated, 
washed five times and 100 µl working detector (biotinylated anti mouse cytokine or 
detection antibody with avidin-horse radish peroxidase conjugate) was added to each well 
and incubated at room temperature for 1 hour. This was followed by an aspiration and 
wash step (>5 washes). The TMB substrate solution (BD Biosciences, Hamburg, 
Germany) was then added to each well at a volume of 100 µl and incubated for 30 
minutes. The stop solution (1 M Phosphoric or 2N Sulphuric acid) was then added to each 
well, and absorbance was measured at prescribed wavelength (nm), using an automatic 
plate reader. Note: Reagents and buffers used in all experimental protocols, double 
distilled water (ddH2O) was used unless stated otherwise.  
 
Griess Assay: The Griess reagent (Promega, Mannheim, Germany) was used for the 
determination of nitrite in cell supernatants as a marker of NO production. The Griess 
Reagent System is based on the chemical reaction that uses sulfanilamide and N-1-
napthylethylenediamine dihydrochloride (NED) under acidic (phosphoric acid) 
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conditions. A protocol provided by the manufacturer was used, in which 1ml of a 100µM 
nitrite solution was prepared by diluting the provided 0.1M Nitrite Standard 1:1,000 in 
the matrix or buffer used for the experimental samples. A 96-microtiter well plate was 
used for the assay and initially a series of standard dilution was prepared using 100µM as 
the highest concentration to 1.5µM as the lowest. The sulfanilamide and NED Solution 
were allowed to equilibrate to room temperature for 15-30 minutes and 50µl of each 
experimental sample was taken into the wells in duplicate or triplicate. Using a 
multichannel pipettor 50µl of sulfanilamide solution was dispensed to all experimental 
samples and wells containing the dilution series for the Nitrite Standard reference curve 
and the plate was incubate for 5–10 minutes at room temperature in dark 50µl of the 
NED Solution was then dispensed to all wells and the plate was incubated for 5–10 
minutes at RT in dark. A purple/magenta colour began to form immediately, which was 
followed by measurement of absorbance within 30 minutes in a plate reader with a filter 
between 520–550nm. A standard was built and the nitrite concentrations in the samples 
was calculated from the equation obtained from the graph 
 
B cell proliferation: Proliferation of B-cells was assessed using CellTiter 96 Proliferation 
Assay (Promega, Mannheim, Germany). The CellTiter 96 Aqueous One Solution contains 
a novel tetrazolium salt compound (MTS) and phenazine ethosulfate that serves as an 
electron-coupling reagent. The solution remains stable normally, while the MTS is 
bioreduced by the NADPH or NADH produced by dehydrogenase enzymes in 
metabolically active cells (such as proliferating cells). The isolated B-cells isolated (1 x 
105) were incubated in 96-well plates in 100 µl complete RPMI medium and treated with 
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1 μM CpG-ODN 1668, 1μg/ml LPS, or various concentrations of ODN 2114 for a period 
of 72 hours under standard culture conditions. To each well with different treatments, 20 
µl CellTiter 96 Aqueous One Solution was added and incubated at 37 °C for 4 hours and 
the optical density (OD) was measured at 492 nm for comparing the cell proliferation. 
 
2.6 Flow cytometric analysis 
In case of splenocytes, BMDCs and mesangial cells, surface staining was performed 
using PE- or FITC-labelled rat anti-CD11c, anti-MHC II, anti-CD86 or anti CD19 
antibodies (BD Pharmingen, Hamburg, Germany). Anti-TLR3 antibody (1:50) was used 
to detect TLR3 on mesangial cells through biotinylated rabbit anti-mouse IgG antibody 
and streptavidin-APC (Pharmingen). A rabbit IgG (BD Pharmingen, Hamburg, Germany) 
was used as isotype control. For intracellular staining, mesangial cells were fixed with 
1% paraformaldehyde and permeabilized with permeabilization buffer (PBS, 0,5% BSA, 
0,5% saponin) at room temperature. FACS analysis was conducted using a FACScalibur 
machine and CellQuest software (BD biosciences, Hamburg, Germany). Primary cells 
were harvested using method described above, involving hemolysis, passage through pre-
separation filter to obtain single cell suspension and wash steps, under cold conditions on 
ice. All cell types, after appropriate stimulation procedures were harvested, resuspended 
in 50-100 µl PBS, and incubated with the respective primary or secondary antibodies 
(wherever applicable) or isotype controls at prescribed dilutions for 30 minutes each, 
followed by a washing step, resuspended in PBS for FACS analysis. Flow cytometry of 
spleen cells for in vivo B cell proliferation and activation assay was performed as 
previously described. Surface staining was performed using PE-labeled rat anti-MHC II 
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or anti CD19 antibodies (BD Pharmingen, Hamburg, Germany). A rabbit IgG (BD 
Pharmingen, Hamburg, Germany) was used as an isotype control. FACS analysis was 
conducted using a FACSCalibur machine and CellQuest software (BD biosciences, 
Hamburg, Germany). 
 
2.7 RNA isolation, cDNA synthesis and real time RT-PCR 
Cultured cells 
Cell lines as well as primary cell cultures in stimulation experiments were harvested for 
RNA isolation using RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to 
the protocol provided. Firstly, adherent cells to be harvested from 6 well culture plates 
were washed with sterile PBS to remove residual medium after collection and the wash-
through was aspirated. 350 µl RLT buffer containing 10µg/ml beta-mercaptoethanol was 
added directly over adherent cells on the plate surface and pipetted vigorously so as to 
lyse cells. This produced a viscous fluid, which was collected and placed in 
microcentrifuge tubes and frozen at –80 °C until RNA isolation. At the time of RNA 
isolation the samples collected were thawed, 350 µl of 70 % ethanol made in 1% Diethyl 
pyrocarbonate treated water (DEPC water) was added to it and mixed well.  This mixture 
was then loaded onto RNeasy mini columns held in 2 ml collection tubes and centrifuged 
at 8000 xg for 30 seconds. The flow-through was discarded and the columns were loaded 
with 700µl of buffer RW1 and centrifuged at 8000 xg for 30 seconds. The collection 
tubes were discarded together with the flow-through and the columns were transferred to 
fresh 2 ml collection tubes and 500 µl of Buffer RPE was pipetted onto the column, was 
centrifuged at 8000 xg for 30 seconds and the flow-through was discarded. This step was 
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repeated again and the column was rendered dry by centrifugation, placed in a 150 µl 
fresh collection tube, 40 µl of RNase free water was pipetted directly on the silica-gel 
membrane and was centrifuged to collect the RNA solution. No quality check was 
necessary in case of the kit isolation, as empirically the RNA obtained upon kit isolation 
was of good quality standards.  
 
Isolation of RNA from tissues 
The RNA isolation protocol was suitably modified from Chomczynski’s method (102). 3 
ml of solution D containing 8µl of beta-mercaptoethanol/ml was taken in a 15 ml falcon 
tube, to which a small piece of tissue from which RNA had to be isolated, was placed. 
The tissue was homogenised using ULTRA-TURRAX T25 (IKA GmbH, Staufen, 
Germany) at speed level 2 and placed on ice. To this 300µl 2M sodium acetate solution 
was added and mixed gently, followed by addition of 3 ml Roti-Aqua-Phenol (Carl Roth 
GmbH, Karlsruhe, Germany) and gentle mixing. A 1.6 ml mixture of chloroform/isoamyl 
alcohol (49:1) was added to the contents of the falcon and vortexed for 20 seconds until a 
milky white suspension resulted. The falcon tube was then placed on ice for 15 min and 
centrifuged at 4000 xg at 4 °C. The upper phase (approximately 3 ml) was collected 
carefully in a fresh falcon tube, to which 3 ml isopropanol was added, incubated for 30 
minutes at –20° C and centrifuged for 15 minutes at 4000 xg at 4 °C. The supernatant 
was then discarded carefully to avoid loss of pellet and the falcon tube was inverted on a 
tissue paper to drain of the remaining isopropanol and 1 ml solution. The pellet was then 
dissolved in 0.5 ml solution D and the solution was transferred to fresh DEPC-treated 
tubes and 0.8 ml Isopropanol was added to it, mixed and placed at –20 for 30 minutes. 
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This was followed by centrifugation for 15 minutes at 4000 xg at 4 °C; the supernatant 
was discarded carefully to retain the pellet. The pellet was then washed with 80 % 
ethanol made in DEPC water, and vortexed again for 15 minutes at 4000 xg at 4 °C. The 
supernatant was discarded and the tubes were inverted to drain of residual ethanol and the 
semi-dried pellet was dissolved in 100 µl DEPC water. A 10µl aliquot was used for the 
quality check and remaining RNA solution was stored at -80 °C until cDNA synthesis. 
The RNA was quantified and quality was determined by taking 2µl of the RNA solution 
diluted 50 times in DEPC water for calculating ratios 260/280 nm spectrophotometric OD 
measurement. The formula used was Extinction x dilution to obtain number of µg/ml of 
RNA per sample and a ratio value approximately close to 1.6 was considered to be of 
acceptable quality. Further quality check (if necessary) was performed using a denaturing 
RNA gel, ran at 70-100 V for 1 hour and the gel was then read on a gel documentation 
apparatus.  
 
cDNA synthesis and real-time RT-PCR   
The RNA samples isolated according to the procedure detailed above were diluted in 
DEPC water to a concentration of 1µg/20µl. A master mix was prepared with reagents 
such as 9 µl of 5x buffer (Invitrogen, Karlsruhe, Germany), 1µl of 25mM dNTP mixture 
(Amersham Pharmacia Biotech, Freiburg, Germany), 2 µl of 0.1 M DTT  (Invitrogen, 
Karlsruhe, Germany), 1 µl of 40U/µl RNasin (Promega, Mannheim, Germany), 0.5µl of 
15µg/ml linear acrylamide (Ambion Ltd, Cambridgeshire, UK), 0.5µl of Hexanucleotide 
(Roche, Mannheim, Germany), 1µl of Superscript (Invitrogen, Karlsruhe, Germany) or 
ddH2O in case of the controls. The master mix was made to a volume of 15µl and added 
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to 1µg/20µl RNA samples were taken in separate DEPC treated microcentrifuge tubes, 
which were mixed and placed at 42 °C on a thermal shaker incubator for 1 hour. After 1 
hour the cDNA samples were collected at placed at -20 °C until use for real-time RT-
PCR analysis. The cDNA samples prepared as described above were diluted 1:10 a 
dilution for the real-time RT-PCR. The real-time RT-PCR was performed on a TaqMan® 
ABI Prism 7000 or 7700 (Applied Biosystems, Darmstadt, Germany). The quantitative 
PCR for mRNA is based on the employment of sequence-specific primers and likewise 
sequence-specific probes. The latter is tagged at both ends with a fluorescent molecule. 
The quencher absorbs TAMRA (at the 3'-End) the fluorescence of the other reporter 
tagged material such as FAM or VIC at the 5'-End. The TaqMan® universal PCR master 
mix (Applied Biosystems, Darmstadt, Germany) contained Taq polymerase possessing a 
5'  3' polymerase activity and a 5'  3 ' exonuclease activity. During the elongation 
phase of the PCR, specifically bound probe was hydrolyzed by the exonuclease and the 
5'-tag was set free. With every newly synthesized DNA strand fluorescent tag material 
was set free and the resulting fluorescence was measured at 488nm. The resulting 
fluorescence signal is directly proportional to the quantity of DNA synthesized. The CT 
value (= "Cycle Threshold") was computed for each sample. This is the cycle number, 
with which the reporter fluorescence signal breaks through a user-defined threshold. The 
TaqMan® universal PCR master mix containing, the forward primers and Reverse 
primers (final concentration of 300 nM) and the probe (final concentration of 100 NM) 
was placed on ice. In the TaqMan® universal PCR master mix contained are PCR 
buffers, dNTPs and the AmpliTaqGold® previously mentioned (Taq polymerase without 
3'  5' exonuclease activity). 18µl of the mastermix was pipetted into each well of a 96-
38 
  
well plate and 2µl of template (DNA dilution) was added to each of these wells. The plate 
was sealed and centrifuged at 280 xg and analyzed using TaqMan® ABI PRISM 7000 or 
7700. For the TaqMan® RT-PCR the following temperature settings were used: The first 
incubation was carried out for 2 minutes at 50°C followed by 95°C for 10 minutes so as 
to activate the polymerase. Templates were amplified during 40 cycles each comprising 
15 seconds incubation at 95°C followed by 1 minute incubation at 60°C. The RT-PCR for 
the housekeepers (18S rRNA or GAPDH) was carried out under similar conditions. The 
CT values were recorded using the ABI PRISM Sequence Detection software (version 
1.0) and the results were evaluated in relation the respective housekeepers. In all cases 
controls consisting of ddH2O were negative for target and housekeeper genes. 
Oligonucleotide primer (300 nM) and probes (100 nM) (Applied Biosystems, Darmstadt, 
Germany) were used: murine CCL5; TLR3 accession number AF355152, forward primer 
5’-CGAAAGTTGGACTTGTCATCAAATC-3’, reverse primer 5’- ACTTGCCAATTG-
TCTGGAAACAC-3’, internal fluorescence probe 5’- CACTTAAAGAGTTCTCCC -3’. 
Primers and probes for murine CCL2, CCL5, and 18S rRNA were obtained as pre-
developed assay reagents from PE Biosystems.  
 
 
 
 
 
 
 
39 
  
3. RESULTS 
3.1 Effects of exposure to viral dsRNA on immune complex glomerulonephritis in 
MRLlpr/lpr Mice 
Infection induced local tissue injury, during lupus nephritis, which is a form of immune 
complex glomerulonephritis, is brought about by local inflammatory cytokine and 
chemokine production by infiltrating immune cells as well as intrinsic renal cells. In 
context of viral infections, exposure of dsRNA and subsequent release of cytokines and 
chemokines can be expected to be mediated through TLR3, leading to local tissue injury 
in kidneys of MRLlpr/lpr mice with lupus nephritis.  
 
3.1.1 Spleen and Kidney TLR3 Expression 
Initially the expression pattern of TLR3 mRNA in kidneys and spleens of MRLlpr/lpr 
mice was determined at an early (week 5) and late (week 20) stage of autoimmune 
disease using real-time RT-PCR. At 5 wk of age, no structural abnormalities were 
detected in kidney and spleen however, TLR3 mRNA in kidneys were comparable to that 
in spleen, indicating that TLR3 is expressed by intrinsic renal in addition to the few 
resident immune cells present in kidneys of 5-wk-old MRLlpr/lpr mice (Figure 2). At 20 
wk, spleens showed major structural abnormalities including lymphoproliferation. At this 
time point, kidneys of MRLlpr/lpr mice revealed severe glomerulonephritis and 
tubulointerstitial injury with interstitial and perivascular inflammatory cell infiltrates. 
Interestingly at 20 wk, spleen TLR3 mRNA levels were unchanged compared with wk 5. 
Proliferative lupus nephritis was associated with somewhat increased renal TLR3 mRNA 
expression, but there was no statistical difference as compared with week 5 (Figure 2).  
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Figure 2. TLR3 mRNA expression in MRLlpr/lpr mice. Expression of TLR3 mRNA 
was assessed by real-time RT-PCR in duplicates using RNA isolated from spleens and 
kidneys from 7 MRLlpr/lpr mice each at 5 weeks and 20 weeks of age as described in 
methods. TLR3 mRNA expression is expressed as ratio to the respective 18S rRNA 
mRNA expression ± SEM (5 vs 20 weeks). At 5 weeks spleens and kidneys did not show 
structural abnormalities. Glomeruli (encircled) show a regular capillary network and 
mesangium. By contrast at 20 weeks spleens showed major structural alterations 
secondary to lymphoproliferative disease indicated by the malformation of spleen lymph 
follicles. At this time point, kidneys showed mesangioproliferative glomerulonephritis 
with periglomerular inflammatory cell infiltrates and tubular atrophy. (Periodic acid 
Schiff stain, original magnification x400). 
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To localize the source of renal TLR3 mRNA expression, immunostaining was performed 
using a polyclonal antibody specific for murine TLR3. Renal sections of 16-wk-old 
MRLlpr/lpr mice revealed positive signals in glomerular mesangial cells but not in 
glomerular endothelial cells or podocytes (Figure 3). Mesangial cell staining for TLR3 
appeared in a speckled pattern, indicating that TLR3 is also localized in an intracellular 
compartment. Mononuclear inflammatory cell infiltrates were also positive for TLR3 
(Figure 3).  
 
3.1.2 Localization of labelled viral dsRNA in mice kidneys 
For examining whether TLR3-positive cells take up circulating viral dsRNA in vivo, 
rhodamine-labeled viral dsRNA was injected intravenously into 16-wk-old MRLlpr/lpr 
mice. Consistent with TLR3 immunostaining in the kidney, the labelled viral dsRNA was 
found in speckled glomerular mesangial cell staining pattern, suggesting that injected 
viral dsRNA was taken up by mesangial cells into an intracellular vesicular compartment 
(Figure 3). Infiltrating cells showed strong granular intracellular signals for labeled viral 
dsRNA. Double labelling with an F4/80-specific antibody identified these cells as 
antigen-presenting cells of the monocyte-macrophage lineage (Figure 3). Rhodamine 
injected alone in MRLlpr/lpr mice was not found to localize in the kidney (data not 
shown). Analysis of spleen sections revealed viral dsRNA signals only in F4/80-positive 
antigen-presenting cells but not in B or T cell areas of the spleen (data not shown). Taken 
together, in the kidneys of MRLlpr/lpr mice, injected viral dsRNA co-localizes in an 
intracellular granular pattern with TLR3-positive cells, i.e., infiltrating mononuclear cells, 
but also with intrinsic renal cells predominantly in glomerular mesangial cells in an 
intracellular vesicular compartment. 
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Figure 3. TLR3 in kidneys of MRLlpr/lpr mice. A: immunostaining for TLR3 was 
performed as described in the methods section. Positive staining was found in 
inflammatory cell infiltrates (arrows), and in glomeruli in a mesangial staining pattern 
(glomerulus encircled). B: negative control staining. C and D: rhodamine-labeled pI:C 
RNA was intravenously injected into four 16 weeks old MRLlpr/lpr mice and renal tissue 
was harvested two hours later. Fluorescence imaging of frozen sections showed uptake of 
labeled pI:C RNA in interstitial cells (arrows in left image of C) and in mesangial cells in 
glomeruli (encircled and at higher magnification in insert of D) consistent with the 
staining pattern for TLR3. Costaining with an FITC-labeled F4/80 antibody identified 
pI:C RNA–positive interstitial cells to be antigen-presenting cells of the monocytic cell 
lineage and illustrates the uptake of rhodamine-labeled-pI:C RNA in intracellular 
endosomes (arrows indicating individual endosomes in right image of C). Original 
magnification of all images 400x.  
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3.1.3 Mesangial cells express TLR3 & secrete CCL2 & IL-6  
To confirm the TLR3 expression by mesangial cells, flow cytometry was performed on 
an established murine mesangial cell line. Under basal culture conditions, TLR3 
expression was detected intracellularly after cell permeabilization, whereas only a little 
surface staining was detected (Figure 4A). To test the functionality of TLR3 on 
mesangial cells, it was examined whether the TLR3 ligand pI:C RNA can induce 
cytokine and chemokine secretion. Stimulation with increasing concentrations of pI:C 
RNA induced IL-6 and CCL2 secretion in a concentration-dependent manner (Figure 
4B). In contrast, pI:C DNA or CpG DNA had no effect on IL-6 or CCL2 production. 
Together, these data indicate that mesangial cells express TLR3 and produce 
proinflammatory cytokines (e.g., IL-6) and CC-chemokines (e.g., CCL2) upon exposure 
to pI:C RNA in vitro.  
 
3.1.4 Production of proinflammatory mediators in APCs 
As TLR3 staining and uptake of labeled pI:C RNA in kidneys of MRLlpr/lpr mice also 
occurred in infiltrating mononuclear cells, spleen monocytes were isolated from 
MRLlpr/lpr mice and cultured. These cells were incubated with pI:C RNA, pI:C DNA, 
CpG-DNA, or medium for 24 h. Splenocytes showed a concentration-dependent increase 
in IL-12p70 and IL-6 release after exposure to pI:C RNA but not after exposure to pI:C 
DNA or CpG-DNA (Figure 5B). In addition, other markers of monocyte activation such 
as NO or the chemokine CCL5 production were determined, as molecules that can 
mediate tissue injury in SLE. pI:C RNA markedly induced CCL5 mRNA expression and 
NO production  
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Figure 4.  pI:C RNA/TLR3 interaction in cultured mesangial cells. Murine mesangial 
cells were cultured as described in methods. A: Flow cytometry for TLR3 before and 
after permeabilization for intracellular staining was performed as indicated. Expression of 
TLR3 (dotted line) is demonstrated by a fluorescence shift compared to the isotype 
control antibody (dark line). B: Cultured cells were incubated with different 
concentrations of either pI:C RNA, pI:C DNA or CpG-DNA or standard medium without 
supplements for 24 hours as indicated. IL-6 and CCL2 production was measured in 
supernatants by Elisa. Results shown are means ± SEM from two comparable 
experiments each performed in duplicate. 
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Figure 5.  pI:C RNA activates spleen monocytes isolated from MRLlpr/lpr mice. A: 
Monocytes from spleens of MRLlpr/lpr mice and incubated with different concentrations 
of either pI:C RNA, pI:C DNA or CpG-DNA or standard medium for 24 hours as 
indicated. IL-6, IL-12p70 and IFN-α production were measured in supernatants by Elisa. 
Results shown are from one of three comparable experiments. n.d. = not done. B: Spleen 
monocytes of MRLlpr/lpr mice were stimulated for 12 hours as above. CCL5 mRNA 
expression was analysed by real-time RT-PCR as described in methods. Values are 
expressed as CCL5 mRNA expression in relation to respective GAPDH mRNA 
expression ± SEM. C: Spleen monocytes of MRLlpr/lpr mice were stimulated for 24 
hours as above. NO production was assessed by measuring nitrite concentrations in 
supernatants using Griess assay as described in methods. Results (for B and C) shown are 
means ± SEM from three comparable experiments, each performed in duplicate. 
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Figure 6.  pI:C RNA activates DCs from MRLlpr/lpr mice. A and B: Flow cytometry 
of CD11c positive BMDCs for CD86 (A) and MHC II (B) was performed as described in 
methods. Cells were incubated with either pI:C RNA (bold dark line) or pI:C DNA 
(dotted line) before analysis. Induction of CD86 and MCH II surface expression in pI:C 
RNA-treated DCs is indicated by a fluorescence shift compared to the isotype control 
antibody (thin black line). C: Cultured cells were treated as above for 24 hours and IL-
12p70, IL-6, and IFN-α production was assessed by Elisa in culture supernatants. Results 
shown are means ± SEM means from two comparable experiments, each performed in 
duplicate. D. DCs of MRLlpr/lpr mice were stimulated for 12 hours as above. CCL5 
mRNA expression was analysed by real-time RT-PCR as described in methods. Values 
are expressed as CCL5 mRNA expression in relation to respective GAPDH mRNA 
expression ± SEM. Results shown are two comparable experiments, each performed in 
duplicate. 
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by spleen monocytes of MRLlpr/lpr mice compared to stimulation with pI:C DNA and 
CpG-DNA (Figure 5A, 5B, and 5C). Next BMDCs were prepared from MRLlpr/lpr mice 
and were incubated with pI:C RNA, pI:C DNA, or medium for 24 hours. Flow cytometric 
analysis for CD86 and MHC II on CD11c-positive BMDC showed a marked increase in 
the surface expression of both molecules with pI:C RNA, indicating BMDC maturation, 
which was absent, with pI:C DNA (Figure 6A). Furthermore, pI:C RNA but not pI:C 
DNA stimulated the secretion of IL-12p70, IL-6, and IFN-α as determined by ELISA in 
culture supernatants of so stimulated BMDCs (Figure 6B). These data indicate that pI:C 
RNA induces the production of proinflammatory mediators such as IL-12p70, IL-6, 
CCL5, and NO production in spleen monocytes and IL- 2p70, IL-6, and IFN-α in BMDC 
of MRLlpr/lpr mice. 
 
3.1.5 Serum IL-6, IL-12p70 and IFN-α levels  
As intermittent viral infections that can lead to immune activation and cytokine release 
are associated with disease flares during ongoing lupus, it was tested if viral dsRNA can 
induce cytokine release in vivo. Further having demonstrated the effect of pI:C RNA on 
IL-6, IL- 12p70, and IFN-α secretion in dendritic cells and macrophages isolated from 
MRLlpr/lpr mice in vitro, serum levels of these factors 6 h after intraperitoneal injection 
of 50 μg of pI:C RNA, 50 μg of pI:C DNA, or saline were determined in 16-wk-old 
MRLlpr/lpr mice. Injection of pI:C RNA caused an increase of serum levels of IL-12p70, 
IL-6, and IFN-α as compared with saline or pI:C DNA in MRLlpr/lpr mice (Figure 7).  
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Figure 7. Serum IL-6, IL-12p70 and IFN-α levels in MRLlpr/lpr mice. Serum was 
obtained from 5-8 16 weeks old MRLlpr/lpr mice 6 hours after the first intraperitoneal 
injection of either saline, 50 mg pI:C RNA or 50 mg pI:C DNA as indicated.  Serum IL-
6, IL-12p70 and IFN-α levels were determined by Elisa. Data are means ± SEM. * 
p<0.05 vs saline. 
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3.1.6 Aggravation of renal damage and proteinuria  
sure to pI:C RNA would aggravate 
pI:C RNA–treated mice (Figure 8, Table 4). 
From the above results, one would predict that expo
lupus nephritis in autoimmune MRLlpr/lpr mice. In this study lupus mice were treated 
with intraperitoneal injections of either 50 μg of pI:C RNA or pI:C DNA or saline on 
alternate days from weeks 16 to 18 of age. Saline-treated MRLlpr/lpr mice had diffuse 
proliferative glomerulonephritis with moderate mesangial hypercellularity, increase of 
mesangial matrix, and little periglomerular inflammatory cell infiltrates at week 18. pI:C 
DNA injections did not alter these histopathologic findings (Figure 8). By contrast, pI:C 
RNA injections induced focal segmental necrosis in glomeruli and cellular crescent 
formation associated with marked periglomerular inflammatory cell infiltrates (Figure 8). 
Aggravation of renal disease was illustrated by an increase in the activity and chronicity 
scores of the lupus nephritis in pI:C RNA treated MRLlpr/lpr mice as compared with the 
other groups of mice (Table 4). pI:C RNA increased the amount of glomerular ER-HR3–
positive macrophages and CD3-positive lymphocytes as compared with pI:C-DNA– and 
saline-injected controls (Table 4). There was a trend toward increased proteinuria levels 
in pI:C RNA–treated mice, but this did not reach statistical significance (Table 4). In 
addition to the aggravation of glomerular damage, pI:C RNA injections induced 
tubulointerstitial damage and fibrosis. Infiltrating ERHR-3 macrophages and CD3 
lymphocytes accumulated particularly in periglomerular fields and areas around 
glomerular crescents (Figure 8, Table 4). To assess extent of interstitial injury, 
immunostaining for smooth muscle actin–positive interstitial myofibroblasts and for 
interstitial collagen I deposits was done. Both were significantly increased in kidneys of 
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ice from 
r ERHR-3 
smooth muscle antigen for myofibroblasts), 
nd collagen I as indicated. Insert in PAS stained sections of pI:C RNA-treated 
Figure 8. Renal histopathology. Renal sections of 18 weeks old MRLlpr/lpr m
all groups were stained with periodic acid Schiff, and antibodies fo
(macrophages), CD3 (lymphocytes), SMA (
a
MRLlpr/lpr mice illustrates necrosis and aneurysm formation of glomerular capillaries 
not detected in other groups (Original magnification x400). Inserts in ER-HR3 and CD3-
stained sections show respective glomeruli at a magnification of x530. Representative 
sections (n= 8-10 mice). 
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Taken together, exposure to pI:C RNA markedly aggravated the immune complex 
glomerulonephritis of MRLlpr/lpr mice toward a crescentic glomerulonephritis with 
mesangiolysis associated with marked tubulointerstitial injury.  
itic cells, and mesangial 
ells, it was hypothesized that pI:C RNA would trigger local chemokine expression in 
C RNA– treated MRLlpr/lpr 
served that activation of TLR9 by bacterial CpG-DNA aggravated 
pus nephritis in MRLlpr/lpr mice in association with enhanced DNA autoantibody 
 
3.1.7 Induction of renal CCL2 and CCL5 mRNA expression 
On the basis of our in vitro studies with macrophages, dendr
c
nephritic kidneys of MRLlpr/lpr mice. In fact, kidneys of pI:
mice showed increased mRNA expression levels for CCL2 and CCL5 (Figure 9A). To 
localize renal CCL2 and CCL5 protein, immunostaining was performed (Figure 9B). At 
18 wk, single spots of CCL5 and CCL2 protein were noted within the glomerular tuft and 
along Bowman’s capsule of some glomeruli, as well as in focal interstitial areas of saline- 
and pI:C DNA–treated MRLlpr/lpr mice kidneys. By contrast, pI:C RNA–treated 
MRLlpr/lpr mice kidneys showed marked CCL2 and CCL5 staining that co-localized 
with interstitial leukocytic cell infiltrates and glomerular crescents (Figure 8). Thus, 
intermittent exposure to pI:C RNA increased local expression of CCL2 and CCL5 in 
areas of pronounced inflammatory cell infiltrates and tissue damage in nephritic kidneys 
of MRLlpr/lpr mice.  
 
3.1.8 Unaffected B Cell activation and DNA autoantibody production in MRLlpr/lpr mice 
Our lab previously ob
lu
production and glomerular immune complex deposits (49). 
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Table 4. Serum, urinary, and histological findings in MRLlpr/lpr mice  
  
saline pI:C DNA pI:C RNA 
     
Functional parameters   
Proteinuria (μg/mg creatinine) 3118 ± 903  2646 ± 694  10405 ± 12173  
 
istological scores  
8.1 ± 2.8 6.6 ± 4.2  15.6 ± 4.2 a  
cells/glom. ]    
 (ce /glom)   
ell glom)     
   
Interst.    EHR3+ (cells/hpf)     6.0 ± 2.9   7.2 ± 5.3   15.5 ± 4.7 a
.7 ± 3.3  17.0 ± 6.4  35.1 ± 10.2 a
  11.0 ± 1.2
 
 a
response 
 IgG 14231 ± 3519 16603 ± 3089 17718 ± 3375 
 IgG2a  10667 ± 3556 9000 ± 3500 7556 ± 3951 
    
Glom. deposit score     
1.2 ± 0.2 1.3 ± 0.4 1.4 ± 0.2 
 
 H  
Activity index  
Chronicity index  
  
1.8 ± 1.0  
 
1.3 ± 0.3 
 
   5.4 ± 2.1a   
 
Cellular response  [  or hpf
Glom.    EHR3+ lls 1.7 ± 0.7 1.9 ± 1.5 4.4 ± 1.6 a
               CD3+ (c s/   1.4 ± 0.4   1.5 ± 0.8   2.2 ± 0.5 a
  
                 CD3+  (cells/hpf)      13  
                SMA+ (% hpf)         5.0 ± 0.8    4.2 ± 3.9  a
 
Interstitial collagen (% hpf) 
  2.9 ± 1.5   3.1 ± 1.7  8.4 ± 4.8
  
Humoral     
Serum titres  
   
  Anti-DNA
  Anti-DNA
 
 
   
  IgG   
  IgG2a   0.3 ± 0.2 0.4 ± 0.3 0.6 ± 0.3 
 
 from ice per group, a p < 0.05 pI:C RNA vs. pI:C DNA 
 
Values are means ± SEM  8-10 m
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Fi
nd CCL5 (B) in kidneys of 18 wk MRLlpr/lpr mice was determined by real-time RT-
PCR using total renal RNA. mRNA levels for saline, pI:C DNA, and pI:C RNA-treated 
RLlpr/lpr mice are expressed in relation to the respective 18S rRNA expression of each 
idney. Results are means ± SEM from 3-5 mice in each group. C. Immunostaining for 
gure 9. Renal expression of CC-chemokines. The mRNA expression of CCL2 (A) 
a
M
k
CCL2 and CCL5 was performed as described in methods. Injection of pI:C RNA 
markedly increased CCL5 expression in spatial association with increasing interstitial 
leukocytic cells and cellular crescents. CCL2 was stained in occasional glomerular cells 
and proximal tubular cells of saline- and pI:C DNA-treated MRLlpr/lpr mice. Injection 
of pI:C RNA increased interstitial CCL2 staining. Arrows indicate chemokine positive 
cells. Sections stained with an isotype control antibody showed no signal (not shown). 
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In this study, predominance of the IgG2a autoantibody and renal IgG deposits of the 
IgG2a isotype suggested a predominant Th1 response induced by bacterial CpG-DNA 
(49). Therefore, in the present study, the effects of pI:C RNA or pI:C DNA on serum 
nti-DNA antibody titres and glomerular IgG deposits were examined in MRLlpr/lpr a
mice. In the current study, irrespective of treatment provided all mice groups had 
comparable titres of total serum DNA IgG or IgG2a autoantibodies (Table 4). Consistent 
with these results, capillary and mesangial deposits of total IgG and of IgG2a in 
glomeruli were comparable in all treatment groups (Table 4). Though, human and murine 
B cells lack TLR3 expression, B cell activation might occur indirectly through pI:C 
RNA-induced activation of DCs and subsequent activation of T cells. Therefore MHC II 
expression on spleen B cells was determined by flow cytometry 24 h after intraperitoneal 
injection of 500 μg of pI:C RNA, pI:C DNA, or CpG-DNA into MRLlpr/lpr mice 
(Figure 10). In contrast to CpG-DNA, neither pI:C RNA nor pI:C DNA induced MHC II 
expression on CD19-positive spleen B cells, indicating that pI:C RNA does not activate B 
cells in MRLlpr/lpr mice. Together with our previous findings, these data demonstrate 
that bacterial CpG-DNA but not dsRNA induces B cell activation and DNA autoantibody 
production in autoimmune MRLlpr/lpr mice.  
As viral infections are known to induce disease flares in individuals with 
autoimmune pre-disposition such as in ongoing systemic lupus, a role of viral dsRNA for 
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igure 10. B cell activation in MRLlpr/lpr mice. 16 weeks old mice were injected with F
500 ug of either pI:C RNA, CpG-DNA or GpC-DNA. After 24 hours flow cytometry for 
MHC II and CD19 was performed on spleen cell suspensions. Staining spleen cell 
suspensions for MHC II produces two peaks. Left peak represents MHC II negative T 
cells showing no change in number, but became a smaller proportion of the total 
population in CpG-ODN-injected mice as compared to pI:C RNA- and pI:C DNA-treated 
controls. The right peak represents MHC II positive antigen-presenting cells including B 
cells (Figure 9A). When gated for the CD19/MHC II double-positive cell population only 
the B cells of the right peak remain (Figure 9B). B cell activation is indicated by an 
increase in MHC II expression on CD19 positive B cells by CpG-DNA (dotted line) but 
not by pI:C RNA (thick line) or pI:C DNA (thin line). Images are representative for 3 
mice in each group. 
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activating TLR3 leading to aggravation of immune complex glomerulonephrits was 
hypothesized. In this context viral dsRNA is known to activate DCs to secrete type I 
interferons and cytokines which are associated with the disease activity in SLE. The 
above results lead to the observations that immunostaining of nephritic kidney sections of 
autoimmune MRLlpr/lpr mice revealed TLR3 expression in infiltrating antigen-
presenting cells as well as in glomerular mesangial cells. TLR3 positive cultured 
mesangial cells exposed to synthetic polyinosinic-cytidilic acid (pI:C) RNA in vitro 
produced CCL2 and IL-6. pI:C RNA activated macrophages and dendritic cells, both 
isolated from MRLlpr/lpr mice, to secrete multiple proinflammatory factors. In vivo, a 
single injection of pI:C RNA increased serum IL-12p70, IL-6, and IFN-α levels. A 
course of 50 μg pI:C RNA given every other day from week 16-18 of age aggravated 
lupus nephritis in pI:C-treated MRLlpr/lpr mice. Serum DNA autoantibody levels were 
unaltered upon systemic exposure to pI:C RNA in MRLlpr/lpr mice, as pI:C RNA, in 
contrast to CpG-DNA, failed to induce B cell activation. It can therefore be concluded 
that, viral dsRNA triggers disease activity of lupus nephritis by mechanisms different 
than that of bacterial DNA. In contrast to CpG-DNA/TLR9 interaction pI:C RNA/TLR3-
mediated disease activity is B cell independent, but activated intrinsic renal cells e.g. 
glomerular mesangial cells to produce cytokines and chemokines, factors that can 
aggravate autoimmune tissue injury e.g. lupus nephritis. 
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3.2 Synthetic G-rich DNA suppresses systemic autoimmunity in MRLlpr/lpr mice 
It is known that CpG-DNA can aggravate autoimmune tissue injury locally by activation 
of tissue macrophages (50). It is also known that methylation of CpG-motif prevents their 
stimulatory effect on B cells (14). Additionally, genomic DNA released by dying cells 
can induce APC maturation (15) while known inhibitors of DNA methylation can induce 
SLE in humans (16). Furthermore, in vertebrates inhibitory DNA sequence elements 
counterbalance the immunostimulatory effects of unmethylated CpG-DNA (17). Certain 
synthetic ODNs with such inhibitory motifs have been shown to block CpG-DNA-
induced effects (97, 98, 99). Despite these facts an evidence for a pathogenic role for 
endogenous CpG-DNA is lacking. In order to determine the pathogenic role of 
endogenous CpG DNA in driving lupus, an inhibitory G-rich DNA was used to test its 
ability of block the CpG DNA/TLR9 pathway in vivo in MRLlpr/lpr mice.  
 
3.2.1 ODN 2114 blocks the stimulatory activity of CpG-ODN in vitro 
Initially the functional antagonism of CpG DNA induced effects, by ODN 2114, a 
synthetic G-rich DNA was tested in vitro. ODN 2114 have been reported to block CpG-
ODN-induced NF-κB activation in mouse B cells (98). It was first aimed to confirm this 
blocking effect in murine macrophages. ODN 2114 blocked CpG-ODN-induced CCL5 
(Figure 11A) and NO (Figure 11B) production in J774 monocytes in a dose-dependent 
manner. At equimolar concentrations of CpG-DNA and ODN 2114 the blocking effect of 
ODN 2114 was 100%. By contrast, ODN 2114 did not affect CCL5 or TNF-α production 
induced by LPS (Figures 11C and 11D). These data suggest that ODN 2114 can act as a 
specific antagonist for CpG-ODN-induced activation of mouse monocytes in vitro. 
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3.2.2 ODN 2114 blocks the stimulatory activity of CpG-ODN in vivo 
Next the potential of ODN 2114 to block the reported CpG-ODN-induced toxicity after 
repeated injection was assessed in mice (103). 129Sv mice were treated with daily 
intraperitoneal injections of saline or either 60 μg CpG-ODN, GpC-ODN, ODN 2114, or 
CpG-ODN plus ODN 2114 or saline for 12 days (n=5 in each group). As previously 
reported CpG-ODN induced splenomegaly and lymphadenopathy as compared to saline-
injected mice (103). In spleens and lymph nodes total cellularity was increased and 
follicles were replaced by disorganized collections of activated macrophages (Figure 12). 
All CpG-ODN-treated mice showed hemorrhagic ascites, as compared to saline and ODN 
2114 treated controls while, ODN 2114 completely blocked CpG-ODN induced ascites. 
Livers of these mice revealed multifocal portal inflammatory cell infiltrates associated 
with large areas of necrotic and apoptotic hepatocytes (Figure 12). By contrast, all mice 
that received ODN 2114 injections together with CpG-ODN did not show major signs of 
CpG-ODN toxicity. ODN 2114 also significantly reduced CpG-ODN-induced alterations 
of the microarchitecture in spleens and lymph nodes (Figure 12). Mice that received 
injections with either ODN 2114 or GpC-ODN alone did not show any histopathological 
abnormalities as compared to saline injected mice (not shown), the latter excluding 
unspecific competition of CpG-DNA. These data imply that ODN 2114 can block CpG-
ODN-induced effects in vivo in mice. 
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Figure 11. ODN 2114 block CpG-DNA-induced effects in vitro. Cultured J774 
macrophages were incubated with either CpG-ODN or CpG-ODN with different 
concentrations of ODN 2114 or standard medium without supplements for 24 hours as 
indicated. A. CCL5 was measured in supernatants by Elisa. B. Nitrite was determined by 
the Griess reaction. C and D. J774 macrophages were incubated with either LPS alone or 
LPS with different concentrations of ODN 2114 or standard medium without 
supplements for 24 hours as indicated. CCL5 and TNF-α levels were measured in 
supernatants by Elisa. Results shown are means ± SEM from one out of two comparable 
experiments, each performed in duplicate. 
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Figure 12. ODN 2114 block CpG-DNA-induced effects in vivo. 129Sv mice were 
injected intraperitoneally with saline or 60 µg either of, GpC-ODN, CpG-ODN or CpG-
ODN + ODN 2114 or saline daily for 14 days (n = 5 in each group, saline not shown). 
Respective organs were stained with periodic acid Schiff reagent (PAS, original 
magnification 400x). 
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3.2.3 Renal distribution of labeled ODN 2114 and CpG-ODN  
Both beneficial and toxic effects of CpG-ODN depend on its recognition through TLR9 
(103). In mice TLR9 is known to be expressed by APCs including B cells, DCs, and 
monocytes (84). It has been shown that TLR9 is expressed on infiltrating monocytes but 
is absent on intrinsic renal cells in nephritic kidneys of autoimmune MRLlpr/lpr mice 
(49). Here it is shown that intravenous injection rhodamine-labeled CpG-DNA localizes 
to glomerular immune complex deposits and to CD11c positive DCs and F4/80 
macrophages in nephritic kidneys of MRLlpr/lpr mice, consistent with the 
immunohistochemical staining pattern for TLR9 (49). It was hypothesized that ODN 
2114 would distribute in a similar pattern in nephritic kidneys of 16 weeks old 
MRLlpr/lpr mice. In fact, rhodamine-labeled ODN 2114 was detected in a glomerular 
mesangial and capillary staining pattern (Figure 13A). Costaining with an antimouse-IgG 
antibody showed colocalization of labeled ODN 2114 with glomerular IgG deposits 
(Figure 13B). In some areas ODN 2114 positive granules were negative for IgG (Figure 
13C). Costaining with EHRH-3 antibody identified these granules to be endosomes of 
glomerular macrophages but IgG-ODN2114 double positive endosomes were also 
observed (Figure 13D). Obviously ODN 2114 localized to intracellular endosomes 
similar to CpG-ODN that can interact with TLR9 after receptor redistribution from its 
reservoir in endoplasmic reticulum (95, 96). Thus, in autoimmune MRLlpr/lpr mice with 
lupus nephritis injected ODN 2114 distributes similar to CpG-DNA-containing immune 
complexes including uptake into endosomes of tissue macrophages. 
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Figure 13. Localization of ODN 2114 in kidneys of MRLlpr/lpr mice after 
intravenous injection. Rhodamine-labeled ODN 2114 were I.V. injected into 16 weeks 
old MRLlpr/lpr mice and renal tissue was harvested 2hr later. A. Fluorescence imaging 
of frozen sections showed uptake of labeled ODN 2114 in a mesangial and capillary 
staining pattern (original magnification 400x). B. At higher magnification (630x) the 
granular deposits of ODN 2114 colocalize with IgG deposits in glomerular capillaries 
upon double staining. C. In some areas ODN 2114 positive but IgG negative granula are 
noted (original magnification 1000x). D. Costaining with an EHRH-3 antibody identified 
these granula to be localized within macrophages (original magnification 1000x). E. 
Costaining with a TLR9 antibody showed colocalization of ODN 2114 and TLR9 to an 
intracellular compartment (original magnification 1000x). 
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3.2.4 ODN 2114 reduces autoimmune tissue injury 
Vertebrate DNA contains immunostimulatory and -inhibitory nucleotide sequences at a 
much lower ratio as bacteria (17). Thus, inhibitory sequence elements in self DNA may 
suppress the immunostimulatory effects of hypomethylated CpG motifs in self DNA. To 
test whether recognition of self-DNA via TLR9 is a pathogenic factor in SLE in vivo, 
MRLlpr/lpr mice were injected intraperitoneally with 40 µg/ml ODN 2114 on alternate 
day intervals from week 11 to 24 of age and their histopathological injury was compared 
with saline-treated MRLlpr/lpr mice at the end of the study. ODN 2114-treated 
MRLlpr/lpr mice revealed markedly reduced serum IFN-α levels as compared to saline 
controls (Figure 14B). This finding argues for ODN 2114-mediated suppression of 
autoimmunity in MRLlpr/lpr mice because IFN-α is known to be associated with disease 
activity in lupus (104). In addition, IFN-α was recently defined as a key factor in TLR-
mediated autoimmunity (92). Morphometric analysis revealed less tissue injury in 
kidneys and lungs of ODN 2114-treated mice (Table 5). Lungs of ODN 2114-treated 
mice showed less peribronchiolar and perivascular inflammatory cell infiltrates compared 
with saline-treated controls (Figure 14C). In kidneys of MRLlpr/lpr mice, ODN 2114 
significantly reduced numbers of interstitial ERHR-3 macrophages, CD3 lymphocytes, as 
well as Ki-67 positive proliferating cells in glomeruli and the tubular compartment (Table 
5, Figure 14A). As a marker of glomerular injury proteinuria was also reduced in ODN 
2114-treated mice, although glomerular macrophage and CD3 cell counts were similar in 
both groups (Table 5). Thus, injections of ODN 2114 can inhibit the immuostimulatory 
effect of CpG-DNA and prevent autoimmune tissue injury in MRLlpr/lpr mice. 
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Table 5. Serum, urinary, and histological findings in MRLlpr/lpr mice  
  
saline pI:C DNA pI:C RNA 
     
Functional parameters   
Proteinuria (μg/mg creatinine) 3118 ± 903  2646 ± 694  10405 ± 12173  
  
Histological scores    
Activity index  8.1 ± 2.8 6.6 ± 4.2  15.6 ± 4.2 a  
Chronicity index  1.8 ± 1.0  1.3 ± 0.3    5.4 ± 2.1a   
     
Cellular response  [cells/glom. or hpf]    
Glom.    EHR3+ (cells/glom)   1.7 ± 0.7 1.9 ± 1.5 4.4 ± 1.6 a
               CD3+ (cells/glom)       1.4 ± 0.4   1.5 ± 0.8   2.2 ± 0.5 a
     
Interst.    EHR3+ (cells/hpf)     6.0 ± 2.9   7.2 ± 5.3   15.5 ± 4.7 a
                 CD3+  (cells/hpf)      13.7 ± 3.3   17.0 ± 6.4  35.1 ± 10.2 a
                SMA+ (% hpf)         5.0 ± 0.8    4.2 ± 3.9   11.0 ± 1.2 a
  
Interstitial collagen (% hpf) 
  2.9 ± 1.5   3.1 ± 1.7  8.4 ± 4.8 a
  
Humoral reponse     
Serum titers  
   
  Anti-DNA IgG  14231 ± 3519 16603 ± 3089 17718 ± 3375 
  Anti-DNA IgG2a  10667 ± 3556 9000 ± 3500 7556 ± 3951 
     
Glom. deposit score        
  IgG   1.2 ± 0.2 1.3 ± 0.4 1.4 ± 0.2 
  IgG2a   0.3 ± 0.2 0.4 ± 0.3 0.6 ± 0.3 
 
Values are means ± SEM from 8-10 mice per group, a p < 0.05 pI:C RNA vs. pI:C DNA 
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Figure 14. Autoimmune lung injury and Lupus nephritis in MRLlpr/lpr mice. A. 
Renal sections were stained with PAS, EHRH-3, and CD3 as indicated (original 
magnification 400x). Images are representative for 10 mice in each group. Note that 
ODN 2114-treated MRLlpr/lpr mice show less periglomerular, and interstitial 
inflammatory cell infiltrates as compared to saline-treated MRLlpr/lpr mice. B. Serum 
IFN-α levels in 24 weeks old female saline- or ODN 2114-treated MRLlpr/lpr mice were 
determined by Elisa (n=8 in each group), *p<0.05 as compared to saline. C: Lungs 
sections taken from 24 weeks old MRLlpr/lpr mice were stained with PAS. Note that 
ODN 2114-treated MRLlpr/lpr mice show less peribronchiolar and perivascular 
inflammatory cell infiltrates as compared to saline-injected MRLlpr/lpr mice (original 
magnification 200x). 
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Inhibitory ODNs have been reported to prevent organ damage induced by exogenous 
CpG-ODN in various disease models (98, 99). The present study reveals beneficial 
effects of ODN 2114 in the absence of exogenous CpG-DNA implying a pathogenic role 
of endogenous CpG-DNA for autoimmune tissue injury in SLE. This finding does not 
seem to be due to unspecific actions of ODN as in this study and others did not observe 
any modulatory effects of random ODN on autoimmunity in MRLlpr/lpr or other mouse 
strains (103, 49, 50).  
 
3.2.5 Autoantibodies and renal immune complex deposits 
Autoantibody production and immune complex deposition cause renal tissue injury in 
SLE. The effect of ODN 2114 on DNA autoantibody production and immune complex 
deposition was assessed in MRLlpr/lpr mice. At 24 weeks of age ODN 2114-treated 
MRLlpr/lpr mice revealed reduced serum levels of dsDNA-specific IgG1 and IgG2a 
antibodies (Table 5). This result was consistent with the observation that ODN 2114 
reduced glomerular IgG1 or IgG2a deposits, a marker of renal immune complex 
deposition in MRLlpr/lpr mice (Table 5, Figure 3C). These findings are suggestive of an 
inhibitory effect of ODN 2114 on CpG-DNA-induced B cell activation in MRLlpr/lpr 
mice. Therefore, MHC II expression was determined on spleen B cells by flow 
cytometry, 24 hours after a single intraperitoneal injection of 500 µg CpG-ODN, ODN 
2114 or CpG-DNA + ODN 2114 into MRLlpr/lpr mice. CpG-DNA-injected mice 
showed marked increase in MHC II expression on CD19 positive spleen B cells, as 
compared to mice treated with ODN 2114 alone or CpG-ODN together with ODN 2114 
(Figure 3D). 
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Figure 16. Serum dsDNA autoantibody levels and glomerular immune complex 
deposits in MRLlpr/lpr mice. Serum dsDNA autoantibody IgG1 (A) and IgG2a (B) 
levels were determined by Elisa (n=8-10). Data are means ± SEM. * p < 0.05 vs. saline. 
C. Renal sections were stained for IgG1 and IgG2a, as indicated (original magnification 
400x). Note less glomerular IgG1 and IgG2a deposits in ODN 2114-treated MRLlpr/lpr 
mice. Images are representative for 10 mice in each group. 
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Figure 17. B-cell activation in MRLlpr/lpr mice. A. B-cells were isolated from 
MRLlpr/lpr mice as described in Methods. B-cells were incubated with either CpG-
ODN, CpG-ODN plus different concentrations of ODN 2114 or standard medium 
without supplements for 72 hours as indicated. B-cell proliferation was assessed by 
CellTiter 96 proliferation assay. B. B-cells were isolated as before and incubated with 
LPS alone or LPS with different concentrations of ODN 2114 or standard medium 
without supplements for 72 hours as indicated. Results are means ± SEM from one of two 
comparable experiments, each performed in duplicate. 
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These results suggest that ODN 2114 can block CpG-ODN-induced B cell 
activation in MRLlpr/lpr mice in vivo, consistent to what has been previously reported 
from in vitro studies with murine B cells (97). ODN 2114 reduced autoantibody 
production, immune complex deposition, and subsequent renal injury in MRLlpr/lpr mice 
that were not exposed to exogenous CpG-ODN. These data raise the possibility of a 
pathogenic role of endogenous CpG-DNA in driving autoimmunity in MRLlpr/lpr mice. 
Dying cells release DNA particles known to activate immune cells, most likely, through a 
TLR9-dependent mechanism (53). Methylation is another factor in masking 
immunostimulatory effects of vertebrate CpG-DNA (14), and DNA methyltransferase 
inhibitors trigger disease activity in human SLE (16). Obviously, a tight balance for 
controlling adjuvant activity of self DNA exists. The data from the present study supports 
the hypothesis that inhibitory ODN 2114 reduces autoimmunity in MRLlpr/lpr mice by 
interfering with endogenous CpG-DNA. TLR9 ligation by CpG-DNA is currently 
evaluated for multiple therapeutic strategies (76, 78), but may cause serious adverse 
effects (103, 49). Our data implicate a role for endogenous CpG-DNA in the 
pathogenesis in lupus and suggest that targeting TLR9 signaling, e.g. with 
immunosuppressive ODN, may provide a new therapeutic target for SLE.  
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4. DISCUSSION 
4.2 Viral dsRNA aggravates immune complex glomerulonephritis in MRLlpr/lpr 
mice 
Viral infections can aggravate disease activity in pre-existing SLE, but the role of viral 
RNA in this context is hypothetical. In this study a model of spontaneous lupus nephritis, 
a form of immune complex-glomerulonephritis, in MRLlpr/lpr mice was used to study 
the effects of intermittent exposure to pI:C RNA, a structural analogue to viral dsRNA. 
Both DNA autoantibody-dependent and independent mechanisms were examined in 
aggravating lupus nephritis by pI:C RNA. For the first time, this study provides evidence 
for expression of TLR3 on glomerular mesangial cells and for the ability of pI:C RNA to 
induce proinflammatory cytokine and chemokine production in these cells. The process 
of aggravation of autoimmune renal injury in MRLlpr/lpr mice that were exposed to 
circulating pI:C RNA is further facilitated through activation of infiltrating immune cells. 
Interestingly pI:C RNA–induced aggravation of lupus nephritis in MRLlpr/lpr mice is 
independent of B cell activation and DNA autoantibody production, which may relate to 
the cell type specific expression profile of TLR3. In MRLlpr/lpr mice, TLR3 expression 
is restricted to APCs of the monocytic cell lineage, e.g., DCs and macrophages, as well as 
to glomerular mesangial cells, which may play an important role in viral infection-
induced local tissue injury and exacerbation of immune complex glomerulonephritis. 
 
4.1.1 Viral dsRNA activates TLR3 on mesangial cells 
Antiviral host defence requires activation of innate immunity, including the local 
production of type I interferons and chemokines (105, 63). The finding that injected 
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dsRNA localized to TLR3-positive APCs of the monocytic cell lineage and to glomerular 
mesangial cells in kidneys of MRLlpr/lpr mice suggests a role for TLR3 in local immune 
responses in the kidney induced by viral dsRNA. In fact, in kidneys of MRLlpr/lpr mice, 
immunostaining for TLR3 localized to glomerular mesangial cells. This is consistent with 
unexpected high levels of TLR3 mRNA in kidneys of these mice, which is consistent 
with previously published data from healthy murine and human kidneys (106, 107). The 
speckled staining pattern for TLR3 in mesangial cells of nephritic glomeruli of 
MRLlpr/lpr mice is also consistent with the uptake of injected and rhodamine-labeled 
viral dsRNA into an intracellular compartment of mesangial cells in their kidneys. 
Mesangial cells do not express other nucleic acid–specific TLR (TLR7, TLR8, and 
TLR9) (49), so the expression of a functional TLR3 in mesangial cells represents a new 
finding. This study with a murine mesangial cell line confirmed the intracellular 
localization of TLR3 analogous to its localization in APCs (108). Furthermore, some 
surface expression of TLR3 was detected, that has also been observed in other 
nonimmune cell types (e.g., human fibroblasts, intestinal epithelial cells) (69, 109). When 
exposed to pI:C RNA, mesangial cells expressed large amounts of IL-6 and CCL2, two 
proinflammatory mediators that are well known to be involved in progression of 
glomerulonephritis in murine disease models and in human glomerular diseases (49, 
110). From these in vitro studies, it was expected that an increase of local expression of 
proinflammatory chemokines in kidneys of MRLlpr/lpr mice, a prediction confirmed by 
real-time RTPCR of total renal isolates and by immunostaining for CCL2 and CCL5 on 
renal sections of pI:C RNA–treated MRLlpr/lpr mice. pI:C RNA–induced local 
production of CCL2 and CCL5 is likely to be involved in the observed aggravation of 
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lupus nephritis in MRLlpr/lpr mice as both CC-chemokines contribute to the progression 
of lupus nephritis by mediating renal leukocyte recruitment in this disease model (111, 
112) as well as in human lupus nephritis (113, 114). When leukocytes migrate to renal 
lesions, they by themselves become a major source of proinflammatory cytokines and 
chemokines (115). It was found that cells of the monocytic cell lineage located in the 
kidney take up circulating pI:C RNA. Studies with spleen monocytes isolated from 
MRLlpr/lpr mice support the idea that uptake of pI:C RNA by tissue macrophages 
contributes to the local production of proinflammatory mediators, including NO, IL-
12p70, IL-6, IFN-α, and CCL5. Taken together, circulating viral dsRNA, e.g. pI:C RNA, 
is taken up by renal macrophages, DCs, and mesangial cells that express TLR3 in 
intracellular endosomes. Ligation of TLR3 activates these cell types to secrete 
proinflammatory mediators, including type I interferons, cytokines, and chemokines, 
which promote local tissue injury. This innate immune mechanism in response to viral 
dsRNA is detrimental in pre-existing renal inflammation such as immune complex 
glomerulonephritis during lupus. 
 
4.1.2 Viral dsRNA activates APCs but elicits no B Cell response 
A central role for dendritic cells (DCs) for infection-associated exacerbation of pre-
existing autoimmunity is suspected for three reasons: 1) In mice and humans, DCs show 
constitutive expression of most TLRs in mice and humans (60, 65); 2) Ex vivo exposure 
of DCs to the TLR4 ligand LPS and transfer of such cells into mice that are prone to 
autoimmune myocarditis was sufficient to initiate overt myocarditis (89), and 3) ligation 
of TLR4 and TLR9 on DCs blocks the suppressor activity of regulatory T cells via 
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secretion of IL-6 (116). Murine macrophages and DCs express TLR3 (63), but TLR3 is 
restricted to DCs on human leukocytes (65). DCs constantly process self-antigens, but in 
the absence of co-stimulatory molecules, the presented antigen provides T cells with a 
signal for tolerance (117). By contrast, during viral infection, virus-associated TLR 
ligands stimulate DCs to upregulate co-stimulatory molecules and to secrete selected 
cytokines (118). Therefore, DCs are key regulators of both tolerance and antiviral 
immunity and therefore may be crucial for viral infection–induced exacerbation of 
autoimmunity, including SLE (116). In fact, among microbial products, viral dsRNA is a 
potent trigger for DC maturation and for the secretion of type I interferons and Th1 
cytokines (93, 119, 120). pI:C RNA was found to trigger maturation and secretion of IL-
12p70 and IFN-α by DCs isolated from bone marrow of MRLlpr/lpr mice is consistent 
with these studies. Although viral dsRNA–induced IFN-α production is a major 
mechanism of anti-viral immunity (121) elevated IFN-α levels also promote the 
progression of autoimmune tissue injury in SLE (122, 123). Furthermore, TLR3-induced 
secretion of IL-12p70 has a critical role in SLE and lupus nephritis mainly by fostering 
the accumulation of IFN-α producing T cells in the kidney followed by aggravation of 
lupus nephritis (33, 124, 125). In these studies it was observed that pI:C RNA–induced 
elevation of IL-12p70 serum levels was associated with acceleration of immune complex 
glomerulonephritis is consistent with a previous study showing aggravation of lupus 
nephritis by injections of recombinant IL-12 in MRLlpr/lpr mice (33). DC activation can 
induce adaptive B and T cell responses. Thus, one might assume that pI:C RNA–induced 
maturation of DCs would enhance humoral immunity against chromatin, an important 
autoantigen in SLE. It is interesting that in contrast to the TLR9 ligand CpG-DNA (52), 
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pI:C RNA did not affect serum levels and glomerular deposits of DNA autoantibodies. 
As human and murine B cells express TLR9 but not TLR3, a direct stimulatory effect of 
pI:C RNA was not predicted, but B cell activation could be supported by indirect 
mechanisms via dendritic cells and T cells. In fact, the data from this study clearly shows 
that in MRLlpr/lpr mice, systemic exposure to pI:C RNA does not provide a signal for B 
cell activation, consistent with the finding that serum DNA autoantibody levels and renal 
IgG deposits were unaffected by repetitive pI:C RNA injections. These findings are 
consistent with a recent observation that a series of injections with CpG-DNA but not 
with pI:C RNA can severely alter the morphology and functionality of mouse lymphoid 
organs (103). In this study it was observed that pI:C RNA induces the secretion of IL-6 in 
DCs and monocytes isolated from MRLlpr/lpr mice. IL-6 derived from antigen-
presenting cells has been shown to suppress CD4+CD25+ regulatory T cells that inhibit 
the proliferation of autoreactive T cells (116). The role of regulatory T cells in SLE 
remains to be determined (126), but their number is reduced in peripheral blood of SLE 
patients with active disease (127, 128), indicating that disease activity of SLE may be 
linked to the regulatory role of this T cell population. pI:C RNA–induced IL-6 secretion 
therefore may modulate adaptive immunity in SLE independent of B cell responses. 
Overall these findings suggest that, viral dsRNA triggers disease activity of lupus 
nephritis by mechanisms different than that of bacterial DNA. In contrast to CpG-
DNA/TLR9 interaction pI:C RNA/TLR3-mediated disease activity is B cell independent, 
but activated intrinsic renal cells e.g. glomerular mesangial cells to produce cytokines and 
chemokines, factors that can aggravate autoimmune tissue injury e.g. lupus nephritis. 
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4.2 Synthetic G-rich DNA suppresses systemic autoimmunity in MRLlpr/lpr mice 
When MRLlpr/lpr mice are exposed to bacterial or synthetic CpG-DNA, ligation of 
TLR9 on immune cells leads to enhanced dsDNA autoantibody production and 
aggravation of lupus nephritis (52). Similarly, insufficient clearance of nuclear particles 
in lupus may also provide a permanent source of hypomethylated CpG motifs from self 
DNA (104). This mechanism may contribute to a continuous activation of B-cells and 
dendritic cells and perpetuate systemic lupus in humans (14, 92, 53). In the present study 
this hypothetical pathway by blocking potential CpG-DNA-induced immunity was tested 
both in vitro and in vivo with a specific antagonist, i.e. G-rich DNA. Further it was tested, 
if endogenous CpG-DNA were to contribute to the progression of lupus nephritis, 
injections of G-rich DNA should prevent disease progression in MRLlpr/lpr mice with 
experimental lupus.  
 
4.2.1 Synthetic G-rich ODN neutralizes CpG-DNA in vitro 
CpG-DNA is a strong activator of plasmacytoid DCs, macrophages, and B-cells in mice 
(14, 72). CpG-DNA stimulates their antigen-presentation and proinflammatory cytokine 
production that drive subsequent Th1 type responses (72). Lenert, et al. first used the 
ODN 2114 to block CpG-ODN-induced effects on murine B-cells (98). Through this 
study it was confirmed that this antagonistic effect is specific, as G-rich ODN 2114, 
totally prevented CpG-DNA-induced B-cell proliferation or CCL5 and TNF-α production 
by macrophages, but did not modulate LPS-related effects. This antagonism occurs 
proximal to NF-κB activation (98), but the specific site of interaction is yet unknown. In 
this study in vivo colocalization of injected ODN 2114 with glomerular IgG deposits was 
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observed which are complexed with chromatin-particles in nephritic MRLlpr/lpr mice. 
G-rich ODN represent a specific antagonist for CpG-DNA-induced B-cell and monocyte 
activation in mice, which is also confirmed in vivo by experiments in Sv129 mice. G-rich 
ODN 2114 blocked CpG-ODN-induced lymphoproliferation, an effect shown to be 
mediated through TLR9 on marginal zone B-cells and monocytes (103) Together, G-rich 
ODN 2114 specifically block the effects of CpG-DNA in vitro and in vivo which renders 
ODN 2114 a valuable tool to address the question, whether endogenous CpG-DNA can 
modulate systemic lupus erythematosus. 
 
4.2.2 G-rich DNA modulates systemic autoimmunity 
In MRLlpr/lpr mice lymphoproliferation and dsDNA autoantibody production progresses 
with age. G-rich ODN 2114 injections reduced spleen weight, as a marker of 
lymphoproliferation, and serum dsDNA autoantibody levels as compared to saline-
injected MRLlpr/lpr mice. As the MRLlpr/lpr mice were not exposed to exogenous CpG-
DNA the observation may be attributed to a blockade of immunostimulatory effects of 
endogenous CpG-DNA on B-cells. This is consistent with a study published by 
Leadbetter et al. showing that self chromatin-containing immune complexes stimulate B-
cells isolated from MRLlpr/lpr mice via TLR9 (77). It is noteworthy that, suppressive 
ODN as well as DNase treatment of the immune complexes abrogated this effect, 
supporting the role for the endogenous CpG-DNA in this context (77). In this study the 
blocking effect of G-rich DNA on B-cell proliferation was specific for CpG-DNA, 
because ODN 2114 did not modulate LPS-induced B-cell proliferation.  
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Serum IFN-α levels depict the activation of IFN-producing plasmacytoid dendritic 
cells (DCs) which represents another marker for disease activity in lupus (129). Nuclear 
particles released from dying cells and complexed with lupus patient IgG are potent 
inducers of IFN-α production in plasmacytoid DCs, an effect sensitive to DNAse 
digestion (87). In a recent study immune complexes were isolated from sera of patients 
with various rheumatic diseases (98). It was found that only DNA-containing immune 
complexes isolated from lupus patients stimulated plasmacytoid DCs to produce 
cytokines and chemokines via a cooperative interaction between TLR9 and FcγRIIa 
(CD32). CD32 shuttles DNA-containing immune complexes into a subcellular 
compartment containing TLR9 (96). Only CD32 positive plasmacytoid DCs internalized 
DNA-immune complexes and produced large amounts of IFN-α. Results from the present 
study show that MRLlpr/lpr mice injected with G-rich DNA show lower serum IFN-α 
levels as compared to saline-injected MRLlpr/lpr mice is in favour of a blocking effect of 
G-rich DNA on interferon-producing plasmacytoid DCs. Thus, G-rich DNA can block B-
cell proliferation, dsDNA autoantibody production, and IFN-α release in mice, which all 
have established etiopathogenic roles in the systemic autoimmunity of lupus 
erythematosus.  
 
4.2.3 G-rich DNA prevents tissue injury in MRLlpr/lpr mice 
MRLlpr/lpr mice injected with G-rich DNA had markedly reduced renal and pulmonary 
autoimmune tissue injury as compared to saline-injected mice. In part this may relate to 
the reduced anti dsDNA antibody production and immune complex deposition, as 
demonstrated for the kidney. However, injected G-rich ODN 2114 could also interact 
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locally with immune complexes and TLR9 positive immune cells. This issue was 
addressed by injecting fluorescently labeled ODN 2114 into nephritic MRLlpr/lpr mice. 
In fact, ODN 2114 localized to glomerular immune complex deposits and to intracellular 
compartments of infiltrating glomerular macrophages. This cellular distribution was 
comparable to that of TLR9 immunostaining in kidneys of MRLlpr/lpr mice. Thus, ODN 
2114 could interfere with CpG-DNA–rich chromatin-immune complexes in the 
endosomes of intrarenal macrophages in vivo. This could reduce a proinflammatory effect 
of the immune complexes on macrophages and possibly DCs in kidneys of MRLlpr/lpr 
mice. Our laboratory has previously shown that exogenous bacterial or CpG-DNA 
markedly stimulate renal macrophages in lupus nephritis of MRLlpr/lpr mice and 
antigen-induced immune complex glomerulonephritis (49, 52). CpG-DNA stimulates 
macrophages to produce multiple proinflammatory mediators that contribute to the 
progression of renal disease. Similarly, exogenous CpG-DNA can cause macrophage-
dependent arthritis or lung injury, which both can be blocked with G-rich DNA (99, 130). 
However, in the present study MRLlpr/lpr mice were not exposed to exogenous CpG-
DNA, so that the beneficial effect of G-rich DNA is through blockade of endogenous 
CpG-DNA-mediated effects. The data from the present study supports the hypothesis that 
endogenous CpG-DNA–rich chromatin activates TLR9 positive immune cells – 
specifically B cells, macrophages, and DCs, and thus contributes to the pathogenesis of 
lupus. Apart from the experimental data in mice, this concept is also supported by the 
therapeutic properties of chloroquine, an unspecific blocker of endosomal TLR 
activation, in the treatment of human lupus (131). The present observation from these 
studies, that administration of G-rich DNA attenuates the course of the lupus-like disease 
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in MRLlpr/lpr mice also argues in favour of endogenous CpG-DNA fragments as 
pathophysiological contributors to disease and indicate that G-rich DNA as a potential 
therapeutic agent for the treatment of SLE. 
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5. ZUSSAMENFASSUNG 
Frei oder in Immunkomplexen gebundene Nukleinsäuren können zu Immunaktivierung 
und damit Verschlechterung vorbestehender Autoimmunkrankheiten führen. Die Toll-
like Rezeptoren TLR3 und TLR 9 erkennen virale und bakterielle Nukleinsäuren. pI:C 
RNA, eine synthetische Doppelstrang-RNA mit identischen immunstimulatorischen 
Eigenschaften wie virale dsRNA aktiviert TLR3 und führt zur m Verschlechterung einer 
vorbestehenden Lupusnephritis in MRLlpr/lpr Mäusen. Dies geschieht durch Aktivierung 
von TLR3 auf antigen-präsentierenden Zellen und glomerulären Mesangialzellen, was 
zur vermehrten lokalen Zytokin- und Chemokinproduktion führt. In gleicher Weise 
aggraviert CpG DNA, ein klassischer Ligand für TLR9 die Lupusnephritis dieses 
Mausmodells, doch die Mechanismen unterscheiden sich von den Effekten von dsRNA. 
Offensichtlich sind die Mechanismen Infekt-getriggerter Immunstimulation abhängig von 
der Zelltyp-spezifischen Expression entsprechender “pattern-recognition” Rezeptoren. 
dsRNA-induzierte Krankheitsaktivität ist unabhängig von einer B Zell Aktivierung und 
der Produktion von DNA Autoantikörpern, was hingegen einen wichtigen Mechanismus 
der CpG-DNA–induzierten Autoimmunität darstellt. Diese Daten fördern das Verständnis 
der Infekt-getriggerten Autoimmunität könnte jedoch auch eine Rolle bei anderen 
Immunkomplex-vermittelten Nierenerkrankungen wie z.B. der IgA Nephritis, den 
renalen Manifestationen der chronischen Hepatitis C Virus Infektion und der renalen 
Vaskulitis spielen. Darüberhinaus besteht die Frage, inwiefern endogene DNA viw TLR9 
an der Pathogenese der Lupusnephritis beteiligt ist. Hier wird gezeigt, die G-reiche DNA, 
ein Inhibitor der CpG-DNA induzierten TLR9 Aktivierung, den Spontanverlauf der 
Lupusnephritis von MRLlpr/lpr Mäusen günstig beeinflusst. Die Blockade von TLR9 
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ermöglicht so ein neues Verständnis der Pathogenese der Lupusnephritis und zeigt neue 
Behandlungsmöglichkeiten auf. 
 
5. SUMMARY 
Nucleic acids that occur free or as immune complexes may trigger immune activation 
leading to aggravation of diseases with autoimmune predisposition. TLR3 and TLR 9 
represent receptors that signal for viral and bacterial nucleic acids respectively. pI:C 
RNA, a synthetic double stranded RNA with identical properties to that viral origin 
activates TLR3 led to aggravation of lupus nephritis, a form of immune complex 
glomerulonephritis, in pre-existing lupus in MRLlpr/lpr mice. Exposure to pI:C RNA (a 
structural analogue of viral dsRNA) can aggravate lupus nephritis through TLR3 on 
antigen-presenting cells and glomerular mesangial cells. pI:C RNA–induced cytokine and 
chemokine production represents a major mechanism in this context. Likewise, CpG 
DNA a classical activator for TLR-9 led to disease aggravation in this mouse model 
albeit, through mechanisms that shared some commonality as well as differences to that 
observed with pI:C RNA. Apparently, pathogen associated immunomodulation relates to 
the cell-type-specific expression pattern of the respective pattern-recognition receptor. 
dsRNA-induced disease activity is independent of B cell activation and humoral 
antichromatin immunity in experimental SLE and therefore differs from CpG-DNA–
induced autoimmunity. These findings contribute to the understanding of pathogen-
associated modulation of autoimmunity but may also be involved in the pathogenesis of 
other types of inflammatory kidney diseases, e.g., flares of IgA nephropathy, renal 
manifestations of chronic hepatitis C virus infection, and renal vasculitis. Further, besides 
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signifying the role of foreign and self-DNA as a pathogenic factor in autoimmune disease 
activity in lupus, this detailed study reveals, that certain synthetic G-rich nucleic acids 
may potentially block nucleic acid specific TLR functions and thus prove beneficial in 
arresting disease activity during progressive systemic lupus. One such G-rich DNA 
employed in this study has proven to be beneficial and suppressed systemic lupus in 
MRLlpr/lpr mouse model. Thus, modulating the CpG-DNA - TLR9 pathway may offer 
new opportunities for the understanding and treatment of lupus. 
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